Picosecond laser apparatus and methods for treating target tissues with same

Information

  • Patent Grant
  • 10581217
  • Patent Number
    10,581,217
  • Date Filed
    Monday, March 25, 2019
    5 years ago
  • Date Issued
    Tuesday, March 3, 2020
    4 years ago
Abstract
Apparatuses and methods are disclosed for applying laser energy having desired pulse characteristics, including a sufficiently short duration and/or a sufficiently high energy for the photomechanical treatment of skin pigmentations and pigmented lesions, both naturally-occurring (e.g., birthmarks), as well as artificial (e.g., tattoos). The laser energy may be generated with an apparatus having a resonator with the capability of switching between a modelocked pulse operating mode and an amplification operating mode. The operating modes are carried out through the application of a time-dependent bias voltage, having waveforms as described herein, to an electro-optical device positioned along the optical axis of the resonator.
Description
FIELD OF THE INVENTION

The present invention relates to an apparatus and methods for delivering laser energy having a short pulse duration (e.g., less than about 1 nanosecond) and high energy output per pulse (e.g., greater than about 200 millijoules).


SUMMARY OF THE INVENTION

Disclosed herein are subnanosecond pulse duration laser systems, which are useful for a variety of cosmetic and medical treatments. A subnanosecond pulse duration laser apparatus includes: (a) a resonator having a first mirror at one end of said resonator and a second mirror at the opposite end of said resonator, wherein both said first mirror and said second mirror are substantially totally reflective; and (b) a lasing medium, an ultrafast switching element and a polarizing element along the optical axis of said resonator, wherein a first drive circuit is connected to a first end of the ultrafast switching element and a second drive circuit is connected to a second end of the ultrafast switching element, wherein said apparatus generates a modelocked pulse by the first circuit applying a periodic voltage waveform to the first end of the ultrafast switching element and then amplifies the modelocked pulse by the first circuit applying a first constant voltage to the first end of the ultrafast switching element and maintaining an effective reflectivity of the second mirror at substantially 100%, and then extracts the amplified modelocked pulse by the second circuit applying a second constant voltage to the second end of the ultrafast switching element and maintaining an effective reflectivity of the second mirror at substantially 0%.


Subnanosecond pulse duration laser systems that are useful for cosmetic and medical applications provide pulsed laser energy that delivers at least about 100 mJ/pulse and up to about 800 mJ/pulse. An exemplary output energy has about 200 mJ/pulse. Likewise, such subnanosecond laser systems have pulse durations of about 100 picoseconds to less than 1000 ps, and preferably pulse durations of about 200 ps to 600 ps, or about 400-500 ps.


Subnanosecond laser systems are particularly useful in the treatment of skin and skin lesions. For example, tattoo removal requires delivery of subnanosecond laser pulses to the dermis, where photomechanical damage to ink particles facilitates the removal of the tattoo by the subject's immune system. Colored tattoos or heavily shaded tattoos are easily treated by such subnanosecond systems, using fewer treatments to achieve a desired reduction in the visible appearance of the tattoo. Other skin treatments include benign pigmented lesions, where applying subnanosecond pulsed laser energy to benign pigmented lesions decreases the visible appearance of the pigmented lesions. Similar effects are seen in the treatment of vascular lesions, where applying subnanosecond pulsed laser energy to the vascular lesion thereby decreases the visible appearance of the vascular lesions.


In addition to pigmented lesions, scars, wrinkles and striae are also treatable using subnanosecond pulsed laser energy. The laser energy can be used to debulk the scars, and it creates generally areas in the tissue of microdamage from photomechanical effects. This has tissue-inductive effects, resulting in the evening-out of tissue surfaces and the improvement in coloration and texture of the target tissue. In certain aspects of the invention, the subnanosecond pulsed laser energy is modified with a lens, thereby producing a treatment beam having a nonuniform energy cross section characterized by of a plurality of regions of relatively high energy per unit area dispersed within a background region of relatively low energy per unit area. Such systems outputting subnanosecond pulse laser energy in a non-uniform beam deliver sufficient energy to target tissue illuminated by regions of relatively high energy per unit area to heat the so-illuminated portions of the target tissue to a first temperature T1 and wherein the substantially uniform background region of relatively low energy per unit area delivers sufficient energy to target tissue illuminated by the regions of relatively high energy per unit area to heat the so illuminated portions of the target tissue to a second temperature T2, wherein T2 is less than T1.


In other embodiments, the invention provides for wavelength shifted subnanosecond pulse laser, that can be frequency matched to the absorption spectrum of a skin pigment or tattoo ink. A method for shifting the wavelength of a subnanosecond pulse laser apparatus includes maintaining a relatively constant pulse duration by using the pulse as a pump for a laser resonator with a short roundtrip time by including a laser crystal with high absorption coefficient at the wavelength of the short pulse; where the round trip time of the short laser resonator is substantially shorter than the pumping laser pulse duration.


The invention will be more completely understood through the following detailed description, which should be read in conjunction with the attached drawings. Detailed embodiments of the invention are disclosed herein, however, it is to be understood that the disclosed embodiments are merely exemplary of the invention, which may be embodied in various forms. Therefore, specific functional details disclosed herein are not to be interpreted as limiting, but merely as a basis for the claims and as a representative basis for teaching one skilled in the art to variously employ the invention in virtually any appropriately detailed embodiment.







DETAILED DESCRIPTION

Lasers are recognized as controllable sources of radiation that is relatively monochromatic and coherent (i.e., has little divergence). Laser energy is applied in an ever-increasing number of areas in diverse fields such as telecommunications, data storage and retrieval, entertainment, research, and many others. In the area of medicine, lasers have proven useful in surgical and cosmetic procedures where a precise beam of high energy radiation causes localized heating and ultimately the destruction of unwanted tissues. Such tissues include, for example, subretinal scar tissue that forms in age-related macular degeneration (AMD) or the constituents of ectatic blood vessels that constitute vascular lesions.


Most of today's aesthetic lasers rely on heat to target tissue and desired results must be balanced against the effects of sustained, elevated temperatures. The principle of selective photothermolysis underlies many conventional medical laser therapies to treat diverse dermatological problems such as leg veins, portwine stain birthmarks, and other ectatic vascular and pigmented lesions. The dermal and epidermal layers containing the targeted structures are exposed to laser energy having a wavelength that is preferentially or selectively absorbed in these structures. This leads to localized heating to a temperature (e.g., to about 70 degrees C.) that denatures constituent proteins or disperses pigment particles. The fluence, or energy per unit area, used to accomplish this denaturation or dispersion is generally based on the amount required to achieve the desired targeted tissue temperature, before a significant portion of the absorbed laser energy is lost to diffusion. The fluence must, however, be limited to avoid denaturing tissues surrounding the targeted area.


Fluence, however, is not the only consideration governing the suitability of laser energy for particular applications. The pulse duration and pulse intensity, for example, can impact the degree to which laser energy diffuses into surrounding tissues during the pulse and/or causes undesired, localized vaporization. In terms of the pulse duration of the laser energy used, conventional approaches have focused on maintaining this value below the thermal relaxation time of the targeted structures, in order to achieve optimum heating. For the small vessels contained in portwine stain birthmarks, for example, thermal relaxation times and hence the corresponding pulse durations of the treating radiation are often on the order of hundreds of microseconds to several milliseconds.


Cynosure's PicoSure™ brand laser system is the first aesthetic laser to utilize picosecond technology which delivers laser energy at speeds measured in trillionth of seconds (10−12). PicoSure systems deliver both heat and mechanical stress to shatter the target from within before any substantial thermal energy can disperse to surrounding tissue. Clinical results show a higher percentage of clearance achieved in fewer treatments. PicoSure systems, employing Pressure Wave™ technology, is useful for multiple aesthetic indications such as pigmented lesions and multi-colored tattoo removal as well as dermal rejuvenation.


An exemplary PicoSure™ brand picosecond laser apparatus is detailed in our U.S. Pat. Nos. 7,586,957 and 7,929,579, incorporated herein by reference. Such a laser apparatus provides for extremely short pulse durations, resulting in a different approach to treating dermal conditions than traditional photothermal treatments. Laser pulses having durations below the acoustic transit time of a sound wave through targeted particles are capable of generating photomechanical effects through pressure built up in the target particles. Photomechanical processes can provide commercially significant opportunities, particularly in the area of treating skin pigmentations. Coupled with high energy output, such lasers described above are particularly suitable for the following exemplary applications. Table 1 provides fluence values for particular spot sizes, for a subnanosecond pulse laser outputting about 200 mJ/pulse.









TABLE 1







PicoSure Fluence










Spot size
J/cm{circumflex over ( )}2














2
6.369



2.5
4.076



3
2.831



3.5
2.080



4
1.592



4.5
1.258



5
1.019



5.5
0.842



6
0.708



8
0.398



10
0.255











A. Tattoo Removal


The incidence of tattoos in the U.S. and other populations, for example, continues at a significant pace. Because tattoo pigment particles of about 1 micron in diameter or less may be cleared from the body via ordinary immune system processes, stable tattoos are likely composed of pigment particles having diameters on the order of 1-10 microns or more. The acoustic transit time of a sound wave in a particle of tattoo pigment is calculated by dividing the radius of the particle by the speed of sound in the particle. As the speed of sound in tattoo pigment, as well as many solid media is approximately 3000 meters/second, the acoustic transit time across such particles, and consequently the laser pulse duration required to achieve their photomechanical destruction of the tattoo pigment is as low as hundreds of picoseconds.


In addition to such short pulse durations, high energy laser pulses are needed for significant disruption of tattoo pigment particles. Given that most tattoos are on the order of multiple centermeters in size, the ideal laser for tattoo removal should ideally employ a beam having a relatively large spot size. Fluences of several joules per square centimeter and treatment spot sizes of a few millimeters in diameter translate to a desired laser output with several hundred millijoules (mJ) per pulse or more, and are suitable for tattoo removal.


An exemplary sub-nanosecond tattoo removal laser apparatus as described in our U.S. Pat. Nos. 7,586,957 and 7,929,579 and as described herein is used to generate pulsed laser energy having a subnanosecond pulse duration of about 100-950 picoseconds, preferably with an energy delivery of about 200-750 mJ/pulse. Such exemplary subnanosecond laser apparatus includes a resonator with two substantially totally reflective mirrors at opposite ends of its optical axis. An alexandrite crystal lasing medium, a polarizer, and a Pockets cell are positioned along this optical axis. An optical flashlamp is also included for pumping the alexandrite lasing medium, which generates laser energy having a wavelength in the range of about 700-950 nm.


The pulsed laser energy described above is generated by pumping the lasing medium and first establishing a modelocked pulse oscillating in the resonator. In the modelocked pulse operating mode, a time-dependent voltage waveform, as described herein, is applied to the Pockets cell. This waveform results from the sum of a constant baseline voltage and a time-dependent differential voltage. The baseline voltage is in the range of 1000-1500 volts (representing 40%-60% of the Pockets cell quarter wave voltage, or 2500 volts) and is negatively offset or modulated by the time-dependent differential voltage, having an amplitude in the range of 250-750 volts (representing 10%-30% of the Pockets cell quarter wave voltage). The period of the resulting voltage waveform is in the range from 5-10 ns and is equal to the round trip time of the oscillating laser energy in the resonator. The voltage applied to the Pockels cell is thus modulated at a frequency in the range from 100-200 MHz.


Subsequently, the modelocked pulse established as described above is amplified by discharging the Pockels cell to essentially 0 volts. Oscillating laser energy is reflected between the mirrors at each end of the resonator, with essentially no losses. This laser energy therefore rapidly increases in amplitude by extracting energy previously pumped and stored in the alexandrite crystal during modelocking. When the laser energy has reached the desired energy level as indicated above, it is extracted from the resonator by applying the quarter wave voltage of 2500 volts to the Pockels cell.


The switching electronics used to operate the laser in modelocked pulse and amplification modes, and finally to extract the amplified pulse as discussed above, comprise five MOFSET switches, two high speed diodes, and three voltage sources having voltages V1 in the range of +1000 to +1500 volts, V2 in the range of +250 to +750 volts, and V3 in the range of −1000 to −1500 volts. The switches, diodes, and voltage sources are configured as shown above.


Laser energy having the pulse duration and energy as described is applied to a patient undergoing treatment for the removal of a tattoo. This laser energy is applied over the course of a 30-minute treatment session to all areas of the skin having undesired tattoo pigment particles. Photomechanical disruption of these particles is effected using the short pulse duration (below the transit time of a sound wave through the targeted tattoo pigment particles), together with a fluence in the range of 2-4 J/cm2. This fluence is achieved in the above device with a laser energy spot diameter of about 5 mm.


Most if not all of the undesired tattoo pigment particles Are effectively photomechanically disrupted, destabilized, and/or broken apart using one or two treatments. As a result, the disrupted particles are cleared from the body via normal physiological processes, such as the immune response. The tattoo is thus eventually cleared from the skin with no remaining visible signs. Such subnanosecond laser devices are particularly well suited for removal of tattoos having colored inks, colors being far more recalcitrant to treatment with traditional laser treatments than black inks. Likewise, tattoos having heavy coloration or shading are more amenable to treatment using subnanosecond laser systems. Similarly, subnanosecond lasers provide for tattoo removal with fewer treatments than compared to traditional laser systems.


B. Benign Pigmented Lesions


Numerous types of benign pigmented lesions of the skin, connective tissue, mucosal tissue and vasculature are treatable using the subnanosecond laser systems described herein.


Nevi are a broad category of generally well circumscribed and chronic lesions of the skin that can be congenital or develop later in life. Vascular nevi such as hemangioma, are derived from structures of the blood vessels. Epidermal nevi such as seborrheic keratoses are derived from keratinocytes. Connective tissue nevi are derived from connective tissues. Melanocytic nevi such as nevomelanocytic nevi are pigmented lesions that morphologically can be flat macules or raised papules, and are characterized by clusters of melanocytes. In addition to the above, dermal melanocytoma (blue nevi), acral nevi, nevus spilus (also known as speckled lentiginous nevus), nevus of Ota/Ito and Becker's nevus are all exemplary and non-limiting nevi that are suitable for treatment using the above laser apparatus.


Lentigines are similarly treatable. These are pigmented spots on the skin typically small and with a clearly-defined edge, surrounded by normal-appearing skin. These are benign melanocytic hyperplasias that are linear rather than raised, with the melanocytes generally restricted to the cell layer directly above the basement membrane of the epidermis. Lentigines also appear in mucosal tissues. Lentigines are distinguished from ephelids (freckles) based on melanocyte proliferation, where lentigines display an increased number of melanocytes but ephelids have normal numbers of melanocytes that overexpress melanin.


Other forms of congenital dermal pigmentation are equally suitable to treatment using the above laser apparatus, usually being larger areas requiring larger laser spot sizes. For example, café au lait macules, congenital dermal melanocytosis, and dermal melanocytosis are all exemplary types of benign, flat, pigmented birthmarks, generally with wavy borders and irregular shapes. Other exemplary pigmented lesions develop as one ages, or due to hormonal changes, infection or treatment with pharmaceutical agents. For example, melasma a/k/a chloasma faciei (colloquially “the mask of pregnancy”) is a tan or dark skin discoloration. Postinflammatory hyperpigmentation (also known as postinflammatory hypermelanosis) can result from natural or iatrogenic inflammatory conditions, and are commonly caused by increased epidermal pigmentation. This can occur through increased melanocyte activity or by dermal melanosis from melanocyte damage with melanin migration from the epidermis into the dermis. Drug-induced pigmentation of the skin may occur as a consequence of drug administration, related to deposition of the drug in the tissues. Minocycline is known for this effect. Pigmented lesions aren't confined to the dermal tissues. Ochronosis is a pigmented lesion caused by the accumulation of homogentisic acid in connective tissues. In addition, melanonychia is aberrant pigmentation of the normal nail plate. These exemplary conditions are all suitable to treatments using the above described laser systems.


To treat the above conditions, it is generally accepted that destruction of melanosomes is pulse-width-dependent. Using traditional laser systems, pulse durations of between 40 nanoseconds and 750 nanoseconds have been shown to be effective, but longer pulse durations (eg, 400 microseconds) do not appreciably damage the melanosomes, Likewise, Q-switched Nd:YAG laser systems have shown immediate skin whitening with threshold energy exposures generating fluence values of 0.11, 0.2, and 1 mJ/cm2 respectively at 355, 532, and 1064 nm wavelengths.


Melanin has a broad absorption spectrum, and lasers emitting at wavelengths of about 500-1100 nm provide for good skin penetration and selective melanosome absorption without undue hemoglobin absorption. Exemplary lasers include 510-nm pulsed dye, 532-nm frequency-doubled Nd:YAG, 694-nm ruby, 755-mn alexaridrite, and near-infrared Nd:YAG lasers emitting at 1064 nm. Other lasers have been used successfully to treat pigmented lesions, including argon, krypton, copper, carbon dioxide, and Er:YAG lasers, but with these systems there is a trade-off between pigment destruction and collateral damage to other chromophores and tissues.


An exemplary subnanosecond laser system for treating pigmented lesions is described by the above apparatus generating pulsed laser energy having a pulse duration of about 100-950 picoseconds with an energy output of about 200-750 mJ/pulse. Laser energy having a wavelength in the range of 700-950 nm provides excellent specificity for melanin. Photomechanical disruption is effected using the short pulse duration (below the transit time of a sound wave through the targeted pigment particles), together with a fluence in the range of 2-4 J/cm2. This fluence is achieved with a laser energy spot diameter of about 5 mm, which can be changed according to the area of the target. Treatment times will vary with the degree of pigmentation and the shapes of the targets. In addition to decreasing the visible appearance of pigmented lesions, photomechanical microdamage to target tissues caused by subnanosecond pulses promotes a healing response that can decrease the size and shape of the lesion.


C. Vascular Lesions


Vascular lesions refer to a broad category of pigmented malformations, generally congenital, that are due to localized defects of vascular morphogenesis. These include capillary, venous, arteriovenous, and lymphatic malformations as well as lesions involving only the skin and subcutaneous tissues. Exemplary non-limiting examples include capillary vascular malformation, telangiectasis, cherry angioma, angiofibroma, dyschromia, port wine stain birthmarks, strawberry hemangiomas, rosacea, pyogenic granuloma and other vascular malformations.


The targeted chromophore for vascular lesions is intravascular oxyhemoglobin, with maximal light absorption occurring in the range of yellow and green light, i.e., at 418, 542, and 577 nm and in the near-infrared spectrum. Traditional approaches to treating vascular lesions involved pulsed dye lasers, typically operating at wavelengths such as 585-nm or 595-nm, frequency-doubled Nd:YAG lasers at wavelengths of 532 nm, and infrared lasers such as alexandrite or diode lasers having wavelengths of 1064 nm. Histologically, the targets of treatment are postcapillary venules, capillaries, or arterioles, generally at depths range from 200 to 300 μm. Accordingly, a deeper penetration of the laser beam is desirable, particularly where heating of the surface skin can lead to excessive scarring. Typical treatment parameters involve fluences of 8 to 10 J/cm2, and a 5-10 mm spot size.


An exemplary system to treat vascular lesions is described by an apparatus generating pulsed laser energy having a pulse duration of about 100-950 ps with energies of about 200-750 mJ/pulse. Laser energy having a wavelength in the range of 500-600 nm provides excellent specificity for oxyhemoglobin. Photomechanical disruption is effected using the short pulse duration (below the transit time of a sound wave through the targeted pigment particles), together with a fluence in the range of 7-10 j/cm2. This fluence is achieved with a laser energy spot diameter of about 5 mm, which can be changed according to the area of the target. Treatment times will vary with the degree of pigmentation and the shapes of the targets.


D. Scar Tissue


Various types of scarring are treatable using lasers. Exemplary non-limiting types include hypertrophic scars, keloids and atrophic scars. Hypertrophic scars are cutaneous deposits of excessive amounts of collagen. These give rise to a raised scar, and are commonly seen at prior injury sites particularly where the trauma involves deep layers of the derrnis, i.e., cuts and bums, body piercings, or from pimples. Hypertrophic scars commonly contain nerve endings are vascularized, and usually do not extend far beyond the boundary of the original injury site.


Similarly, a keloid is a type of scar resulting from injury, that is composed mainly of either type III or type I collagen. Keloids result from an overgrowth of collagen at the site of an injury (type III), which is eventually replaced with type 1 collagen, resulting in raised, puffy appearing firm, rubbery lesions or shiny, fibrous nodules, which can affect movement of the skin. Coloration can vary from pink to darker brown.


Atrophic scarring generally refers to depressions in the tissue, such as those seen resulting from Acne vulgaris infection. These “ice pick” scars can also be caused by atrophia maculosa varioliformis cutis (AMVC), which is a rare condition involving spontaneous depressed scarring, on the cheeps, temple area and forehead.


Laser treatments are suitable for hypertrophic and atrophic scars, and keloids, and common approaches have employed pulsed dye lasers in such treatments. In raised scars, this type of therapy appears to decrease scar tissue volume through suppression of fibroblast proliferation and collagen expression, as well as induction of apoptotic mechanisms. Combination treatment with corticosteroids and cytotoxic agents such as fluorouracil can also improve outcome. In atrophic scars, treatments can even out tissue depths.


Striae (stretch marks) are a form of scarring caused by tearing of the dermis. They result from excess levels of glucocorticoid hormones, which prevent dermal fibroblasts from expressing collagen and elastin. This leads to dermal and epidermal tearing. Generally, 585-nm pulsed dye laser treatments show subjective improvement, but can increase pigmentation in darker skinned individuals with repeated treatments. Fractional laser resurfacing using scattered pulses of light has been attempted. This targets small regions of the scar at one time, requiring several treatments. The mechanism is believed to be the creation of microscopic trauma to the scar, which results in new collagen formation and epithelial regeneration. Similar results can be achieved, albeit to the total scar, through the use of modified laser beams as described in our U.S. Pat. No. 7,856,985, detailing the use of non-uniform beam radiation to create within the beam area, discrete microtrauma sites against a background of tissue inducing laser radiation.


An exemplary system for treating scars is described by the above apparatus generating pulsed laser energy having a pulse duration of about 100-950 ps with energies of about 200-750 mJ/pulse. Laser energy having a wavelength in the range of 500-1100 nm provides excellent specificity for collagen. Photomechanical disruption of the scar tissue is effected using the short pulse duration (below the transit time of a sound wave through the targeted tissue), together with a fluence in the range of 2-4 J/cm2. This fluence is achieved with a laser energy spot diameter of about 5 mm, which can be changed according to the area of the target. Treatment times wilt vary with the degree of scarring and the shapes of the targets. The photomicrodamage from subnanosecond pulses can debulk the scar, resolve coloration differences between it and healthy tissues, and promotes tissue healing responses which have the effect of softening the scar. Modifying the output beam as described in U.S. Pat. No. 7,856,985 provides a particularly useful approach to reducing scar appearance and inducing epithelial restoration within the scar.


E. Dermal Rejuvenation


A non-uniform output beam is delivered to tissue from a source of light as described in our patent applications U.S. Ser. Nos. 11/347,672; 12/635,295; 12/947,310, and PCT/US10/026432. The non-uniform beam is characterized by a cross-section corresponding to an array of relatively small, relatively high-intensity, spaced-apart central regions superimposed on a relatively large, and relatively low-intensity background region. Operatively, this produces within the area of the beam, relatively hotter regions and relatively cooler regions. This non-uniform beam provides for unique physiological effects as compared to standard uniform output laser beams that demonstrate relative uniform energy output across the planar surface of the beam. Such effects are related to the fluence and duration of the light pulse, and include various quantifiable physiological effects. Exemplary temperature dependent effects include but are not limited to parakeratosis, perivascular mononuclear infiltration, keratinocyte necrosis, collagen denaturation, and procollagen expression in dermal cells. Other cellular markers (e.g., nucleic acids and proteins) are useful in detecting more subtle responses of skin to less aggressive treatments.


Various combinations of wavelength, power, spot size, treatment duration and recovery intervals are possible, and the particular combination is selected based on the desired therapeutic effect. For example, in treating age spots and pigmentation a device wavelength is chosen to be preferentially absorbed by melanin (between 400 nm and 1400 nm, and more preferably 500 nm to 1100 nm). Accordingly, an exemplary device for such purposes has a wavelength of about 750 nm, a pulse duration of about 500 to 900 ps and an overall treatment area of 1 cm2 that is output as a non-uniform beam characterized by a cross-section corresponding to an array of relatively small, relatively high intensity, spaced-apart central regions superimposed on a relatively large, relatively low intensity background region. If such exemplary device has about 0.2 J of energy delivered into the treatment area, or about 0.2 J/cm2 average fluence. Using a lens that renders the output beam non-uniform, delivering relatively high intensity spaced-apart central regions at 1 mm center-to-center distances surrounded by low intensity background regions, in such device, there are about 115 discrete subzones (e.g., combined areas of relatively high and relatively low intensity) per square centimeter in that arrangement, which results in about 1.73 mJ delivered to each subzone. Within each subzone, if the high intensity spaced-apart central region is about 120 μm in diameter and approximately 80% of the energy is delivered into the high intensity spaced-apart central regions, then the fluence within each high intensity region is approximately 12.2 J/cm2. That fluence value in the device is comparable to the treatment fluence delivered by high-powered Alexandrite uniform spot lasers having pulse durations of about 50 ns, which are the systems commonly used to treat uneven skin pigmentation in clinical settings by medically trained professionals. Unlike uniform-beam devices, using the non-uniform beam technology for any individual treatment session, only a relatively small percentage of the irradiated skin surface is actually treated with high intensity light, and thereby only a subpopulation of melanocytes receive a cellular disruptive dose of thermal energy, leading to a relatively smaller percentage of melanocyte damage per treatment area compared to uniform beam treatments. This advantageously reduces any sharp boundaries between treated and untreated skin, thereby reducing the need for special operator skills and techniques.


Good cosmetic effects can be produced by such non-uniform irradiation of tissues, due to differential effects occurring in both the relatively high intensity spaced-apart central regions of the beam and in the relatively low intensity background region. By way of illustration, within the spaced-apart central regions it is possible to cause relatively localized heating of tissues therein to a temperature T1 sufficient to heat up the melanocytes to a temperature sufficient to disrupt cellular processes (e.g., about 45 degrees C. or higher), impair their function and decrease their pigment output. Simultaneously during the treatment, within the low intensity background regions at a lower relative temperature T2 (e.g., less than 45 degrees C. to about 35 degrees C.), cellular growth and collagen production is induced without causing undesirable thermal effects to the treated tissue within the lower energy regions. The result of such treatment is an improvement to both skin texture and coloration. Other differential effects on tissues can be realized as well. By way of further example, temperatures at about 70 degrees C. can serve to denature collagen, so within the spaced-apart central regions it is possible to cause relatively localized heating of tissues therein to a temperature T1 sufficient to remodel collagen structures, while simultaneously within the low intensity background regions at a lower relative temperature T2, collagen production is induced without causing undesirable thermal effects to the treated tissue within the background regions.


Likewise, by decreasing the amount of energy delivered by the beam it is possible to select for specific thermal effects on tissues. For example, in our U.S. Pat. No. 7,856,985 we disclose collagen remodeling at temperatures where T1 is approximately 70 degrees C. or greater while the irradiated tissues in the cooler regions of the beam (e.g., at temperature T2) are not substantially adversely affected. The device used generating a non-uniform beam output, permits more selective application with less collateral tissue damage. However, for reducing age spots and evening skin pigmentation, melanocyte cell membrane damage with consequent cellular disruption is achieved at lower T1 temperatures of approximately 45-50 degrees C. (unless such heating is quite transient). Higher temperatures are suitable, and cause permanent disruption of melanocytes, but above 50 degrees C. more extensive thermal effects are seen in the tissue, that must be evaluated against therapeutic benefits. Below the temperature threshold for causing cellular damage and disruption, positive effects on skin tone are seen. At a T1 temperature of less than about 50 degrees C., cells are not substantially damaged but are still induced to generate a healing response and express elastin, procollagen, keratin and other markers for dermal rejuvenation. So a device generating regions capable of elevating tissue temperatures to a T1 of about 45 degrees C. against a background T2 of about 37 degrees.


The overall effect of treatments on skin tone, wrinkling and pigmentation provide the best indication of therapeutic efficacy, but such treatments also leave histological evidence that can be discerned. At higher energies, thermal damage is easy to detect. For more moderate energies, microthermal damage can produce effects that are seen with magnification although erythema provides a good marker for microthermal injury and it does not require microscopic examination of tissues from the treatment site. Generally, in the absence of any visually observable erythema, the cellular effects will be more subtle, or may take longer to manifest themselves or may require multiple treatments before visual improvement of the skin is seen. At lower output energies, shorter pulse durations, and longer intervals between treatments, it is advantageous to use more sensitive techniques to assay for cellular changes. Certain techniques provide for quantitative analysis, which are correlated to describe a dose-response relationship for the non-uniform beam, as it is used in dermal rejuvenation applications. Such techniques include but are not limited to RT-PCR and/or real-time PCR, either of which permits quantitative measurements of gene transcription, useful to determine how expression of a particular marker gene in the treated tissues changes over time. In addition to nucleic acid-based techniques, quantitative proteomics can determine the relative protein abundance between samples. Such techniques include 2-D electrophoresis, and mass spectroscopy (MS) such as MALDI-MS/MS and ESI-MS/MS. Current MS methods include but are not limited to: isotope-coded affinity tags (ICAT); isobaric labeling; tandem mass tags (TMT); isobaric tags for relative and absolute quantitation (iTRAQ); and metal-coded tags (MeCATs). MeCAT can be used in combination with element mass spectrometry ICP-MS allowing first-time absolute quantification of the metal bound by MeCAT reagent to a protein or biomolecule, enabling detection of the absolute amount of protein down to attomolar range.


An exemplary system for dermal rejuvenation is described by the above apparatus generating pulsed laser energy having a pulse duration of about 100-950 ps with energies about 200-750 mJ/pulse. Laser energy having a wavelength in the range of 500-1100 nm provides excellent specificity for collagen. Photomechanical disruption of the target tissue is effected using the short pulse duration (below the transit time of a sound wave through the targeted tissue), together with a fluence in the range of 2-4 J/cm2. This fluence is achieved with a laser energy spot diameter of about 5 mm, which can be changed according to the area of the target. Treatment times will vary according to the desired effects. Modifying the output beam as described in U.S. Pat. No. 7,856,985 provides a particularly useful approach to rejuvenating tissue and inducing collagen and epithelial cell restoration within the tissue.


F. Frequency Shifting


The subnanosecond laser systems may include a frequency shifting apparatus, which can be matched to the absorbtion spectrum of endogenous skin pigmentation or exogenous tattoo pigments to be targeted. Such a system comprises a rare earth doped laser gain crystal for example Nd:YVO4, and a frequency doubling crystal for example KTP. Rare earth doped laser crystals that generate a polarized laser beam like Nd:YVO4 are preferred. Crystals like Nd:YAG or Nd doped glasses can be used with an additional polarizing element in the resonator. The input side of the Nd:YVO4 crystal is AR coated for the alexandrite wavelength and HR coated for 1064 nm. The output side of the crystal is HR coated for the alexandrite wavelength and has approximately 20 to 70% reflectivity at 1064 nm. The Nd:YVO4 crystal length is chosen so that it absorbs most (greater than 90%) of the alexandrite laser pulse in the two passes through the crystal. For Nd doping in the range 1 to 3% the Nd:YVO4 crystal can be chosen to be around 3 mm long. There are no other optical elements in the resonator and the resonator length is equal to the crystal length 3 mm. That means the resonator round-trip time is around 36 ps—this is substantially less than the pulse duration of the alexandrite pumping pulse (around 500 to 800 ps). The 1064 nm pulse generated in the very short round trip time Nd:YVO4 resonator will be slightly longer than the pumping alexandrite pulse and it will be shorter than 1000 ps. The quantum defect will account for a 30% pulse energy loss and another 15% of the energy is likely to be lost due to coatings, crystal and geometry imperfection for an overall energy conversion efficiency of around 50 to 60%. That means a 100 mJ pulse energy can be expected at 1064 nm. Conservatively it is estimated that the second harmonic conversion in the KTP crystal will be around 50% and a 50 mJ pulse energy can be expected at 532 nm. The red tattoo pigments have high absorption at 532 nm. A 50 mJ 532 nm pulse with a pulse duration less than 1000 ps is expected to be effective at disrupting red tattoo granules.


When the Nd:YAG crystal or Nd doped glasses are used in the short resonator an extra polarizing element has to be used to generate a polarized 1064 nm pulse. The cross-section depicts a short Nd:YAG resonator consisting of two identically shaped crystals with one face cut at an angle that is AR coated for the alexandrite wavelength and polarized coating for 1064 nm (high p transmission). The flat faces of the two Nd:YAG crystals have different coatings—one is AR coated at 755 nm and FIR coated at 1064 nm and the other is HR coated for 755 nm and has an output coupler reflectivity around 50 to 80% for 1064 nm. The higher output coupler reflectivity for the Nd:YAG crystal compared to the Nd:YVO4 crystal is due to the lower gain cross-section in Nd:YAG.


Generating a short 1064 nm pulse depends on two factors. One is the pulse duration of the pumping alexandrite pulse. Shorter pumping pulses will lead to shorter generated pulses at 1064 nm. The second factor is the 1064 nm resonator round trip time that is determined by the length of the Nd doped crystal. Shorter crystals lead to shorter roundtrip time, however the crystal has to be sufficiently long to absorb greater than 90% of the alexandrite energy. For example, an 8 mm long Nd:YAG resonator would have a 97 ps round trip time. That round trip time is longer than the round trip time that can be achieved with a Nd:YVO4 resonator, but still it is much shorter than the pumping Alexandrite laser pulse duration. One possible way to shorten the crystal length is to tune the alexandrite laser in the range 750 to 760 nm for maximum absorption in the Nd doped crystal and use the minimum possible crystal length. In addition, tuning the atexandrite laser in the range 750 to 757 nm allows for the alexandrite wavelength to be set to avoid the excited state absorption bands in the Nd ion as described by Kliewer and Powell, IEEE Journal of Quantum Electronics vol. 25, page 1850-1854, 1989.

Claims
  • 1. A method of treating a target tissue comprising: generating, using a laser source, an output beam having a subnanosecond pulse duration;modifying the output beam, using an optical system, to provide a photomechanically disruptive treatment beam;directing the photomechanically disruptive treatment beam to one or more regions of the target tissue;photomechanically disrupting the one or more regions of the target tissue; andinducing collagen restoration within the target tissue in response to photomechanically disrupting the one or more regions of target tissue.
  • 2. The method of claim 1 further comprising rejuvenating the target tissue.
  • 3. The method of claim 2 wherein rejuvenating the target tissue comprises inducing epithelial cell restoration within the target tissue in response to photomechanically disrupting the one or more regions of the target tissue.
  • 4. The method of claim 2 wherein rejuvenating the target tissue comprises increasing amount of collagen disposed therein relative to untreated tissue.
  • 5. The method of claim 1 wherein the photomechanically disruptive treatment beam has a non-uniform beam profile, the non-uniform beam profile comprising a plurality of regions of relatively high energy per unit area dispersed within a substantially uniform background region of relatively low energy per unit area.
  • 6. The method of claim 5 further comprising increasing temperature of a first region of target tissue to a first temperature T1 and increasing or maintaining temperature of a second region of target tissue to a second temperature T2 in response to distribution of regions of relatively high energy and regions of relatively low energy.
  • 7. The method of claim 6 wherein T1 ranges from about 45 degrees Celsius to about 50 degrees Celsius.
  • 8. The method of claim 6 wherein T1 is approximately 70 degrees Celsius or greater.
  • 9. The method of claim 1, wherein the photomechanically disruptive treatment beam has an energy spot diameter of about 5 mm.
  • 10. The method of claim 1, wherein the photomechanically disruptive treatment beam has an energy spot diameter which can be changed according to area of the target tissue.
  • 11. A method of treating a target tissue comprising one or more pigments, the method comprising: generating, using a laser source, an output beam having a subnanosecond pulse duration;modifying the output beam, using an optical system, to provide a photomechanically disruptive treatment beam;directing the photomechanically disruptive treatment beam to one or more pigments of the target tissue, wherein the one or more pigments are visible prior to treatment; anddecreasing visible appearance of one or more pigments within the target tissue in response to the photomechanically disruptive treatment beam.
  • 12. The method of claim 11, wherein the one or more pigments comprise one or more tattoo pigments.
  • 13. The method of claim 11, wherein the target tissue is a pigmented lesion.
  • 14. The method of claim 11 wherein the one or more pigments is melanin.
  • 15. The method of claim 11 wherein decreasing visible appearance of one or more pigments comprises decreasing visible appearance of a pigmented lesion within the target tissue.
  • 16. The method of claim 11, wherein the photomechanically disruptive treatment beam has a non-uniform beam profile, the non-uniform beam profile comprising a plurality of regions of relatively high energy per unit area dispersed within a substantially uniform background region of relatively low energy per unit area.
  • 17. The method of claim 16 further comprising increasing temperature of a first region of target tissue to a first temperature T1 and increasing or maintaining temperature of a second region of target tissue to a second temperature T2 in response to distribution of regions of relatively high energy and regions of relatively low energy.
  • 18. A method of treating tissue comprising oxyhemoglobin, the method comprising: generating, using a laser source, an output beam having a subnanosecond pulse duration;modifying the output beam, using an optical system, to provide a photomechanically disruptive treatment beam;directing the photomechanically disruptive treatment beam to one or more regions of the target tissue comprising oxyhemoglobin, wherein the target tissue comprises a vascular lesion that is visible prior to treatment; anddecreasing visible appearance of the vascular lesion in response to the photomechanically disruptive treatment beam.
  • 19. The method of claim 18, wherein the photomechanically disruptive treatment beam has a non-uniform beam profile, the non-uniform beam profile comprising a plurality of regions of relatively high energy per unit area dispersed within a substantially uniform background region of relatively low energy per unit area.
  • 20. The method of claim 19 further comprising increasing temperature of a first region of target tissue to a first temperature T1 and increasing or maintaining temperature of a second region of target tissue to a second temperature T2 in response to distribution of regions of relatively high energy and regions of relatively low energy.
  • 21. The method of claim 18, wherein the photomechanically disruptive treatment beam has an energy spot diameter of about 5 mm.
  • 22. The method of claim 18, wherein the photomechanically disruptive treatment beam has an energy spot diameter which can be changed according to area of the target tissue.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/721,714, filed Sep. 29, 2017, which is a continuation of U.S. patent application Ser. No. 14/394,960, filed Oct. 16, 2014, now U.S. Pat. No. 9,780,518 issued Oct. 3, 2017, which is a national phase under 35 U.S.C. § 371 of International Application No. PCT/US2013/032228, filed Mar. 15, 2013, which claims priority to and the benefit of U.S. Provisional Patent Application No. 61/625,961 entitled “Picosecond Laser Apparatus and Methods for Treating Dermal Tissues with Same”, filed Apr. 18, 2012, the entire disclosures of which are incorporated herein by reference.

US Referenced Citations (1323)
Number Name Date Kind
853033 Roberts May 1907 A
1590283 Catlin Jun 1926 A
1676183 Garfunkle Jul 1928 A
1706161 Hollnagen Mar 1929 A
2068721 Wappler et al. Jan 1937 A
2472385 Rollman Jun 1949 A
2669771 Burge et al. Feb 1954 A
3243650 Hawkins et al. Mar 1966 A
3261978 Brenman Jul 1966 A
3284665 Goncz Nov 1966 A
3327712 Kaufmann Jun 1967 A
3465203 Michaels et al. Sep 1969 A
3486070 Engel Dec 1969 A
3524144 Buser et al. Aug 1970 A
3527932 Thomas Sep 1970 A
3538919 Meyer Nov 1970 A
3597652 Gates, Jr. Aug 1971 A
3622743 Muncheryan Nov 1971 A
3651425 McKnight Mar 1972 A
3653778 Freiling Apr 1972 A
3667454 Prince Jun 1972 A
3693623 Harte et al. Sep 1972 A
3699967 Anderson Oct 1972 A
3725733 Mack et al. Apr 1973 A
3766393 Herzog et al. Oct 1973 A
3766488 Kohn Oct 1973 A
3769963 Goldman et al. Nov 1973 A
3793723 Kuris et al. Feb 1974 A
3794028 Mueller et al. Feb 1974 A
3815046 Johnson et al. Jun 1974 A
3818373 Chun et al. Jun 1974 A
3818914 Bender Jun 1974 A
3821510 Muncheryan Jun 1974 A
3834391 Block Sep 1974 A
3843865 Nath Oct 1974 A
3846811 Nakamura et al. Nov 1974 A
3857015 Clark et al. Dec 1974 A
3858577 Bass et al. Jan 1975 A
3861921 Hoffmann et al. Jan 1975 A
3885569 Judson May 1975 A
3890537 Park et al. Jun 1975 A
3900034 Katz et al. Aug 1975 A
3909649 Arsena Sep 1975 A
3914709 Pike et al. Oct 1975 A
3939560 Lyall Feb 1976 A
3977083 Leslie et al. Aug 1976 A
3980861 Fukunaga Sep 1976 A
4019156 Fountain et al. Apr 1977 A
4037136 Hoene Jul 1977 A
4038984 Sittner Aug 1977 A
4047106 Robinson Sep 1977 A
4065370 Noble et al. Dec 1977 A
4122853 Smith Oct 1978 A
4133503 Bliss Jan 1979 A
4139342 Sheldrake et al. Feb 1979 A
4154240 Ikuno et al. May 1979 A
4176324 Aldag et al. Nov 1979 A
4188927 Harris Feb 1980 A
4213462 Sato Feb 1980 A
4228800 Degler, Jr. et al. Oct 1980 A
4233493 Nath et al. Nov 1980 A
4254333 Bergstrom Mar 1981 A
4259123 Tymkewicz Mar 1981 A
4269067 Tynan et al. May 1981 A
4273109 Enderby Jun 1981 A
4275335 Ishida et al. Jun 1981 A
4291281 Pinard et al. Sep 1981 A
4292601 Aldag et al. Sep 1981 A
4293827 McAllister et al. Oct 1981 A
4298005 Mutzhas Nov 1981 A
4299912 Shiba et al. Nov 1981 A
4302730 Jernigan Nov 1981 A
4313431 Frank Feb 1982 A
4316467 Muckerheide Feb 1982 A
4335726 Kolstedt May 1982 A
4336809 Clark May 1982 A
4333197 Kuris Jun 1982 A
4364015 Drake et al. Dec 1982 A
4375684 Everett May 1983 A
4388924 Weissman et al. Jun 1983 A
4409479 Sprague et al. Oct 1983 A
4428368 Torii Jan 1984 A
4435808 Javan Mar 1984 A
4445217 Acharekar et al. Apr 1984 A
4452081 Seppi Jun 1984 A
4456872 Froeschle Jun 1984 A
4461294 Baron Jul 1984 A
4488104 Suzuki Dec 1984 A
4489415 Jones et al. Dec 1984 A
4492601 Nakasone et al. Jan 1985 A
4503854 Jako Mar 1985 A
4504727 Melcher et al. Mar 1985 A
4512197 von Gutfeld et al. Apr 1985 A
4524289 Hammond et al. Jun 1985 A
4539987 Nath et al. Sep 1985 A
4553546 Javelle Nov 1985 A
4555786 Byer Nov 1985 A
4556979 Scott et al. Dec 1985 A
4559943 Bowers Dec 1985 A
4561440 Kubo et al. Dec 1985 A
4566271 French et al. Jan 1986 A
4566438 Liese et al. Jan 1986 A
4569345 Manes Feb 1986 A
4576177 Webster, Jr. Mar 1986 A
4587968 Price May 1986 A
4591762 Nakamura May 1986 A
4592353 Daikuzono Jun 1986 A
4601037 McDonald Jul 1986 A
4601753 Soileau et al. Jul 1986 A
4608978 Rohr Sep 1986 A
4608979 Breidenthal et al. Sep 1986 A
4617926 Sutton Oct 1986 A
4623929 Johnson et al. Nov 1986 A
4629884 Bergstrom Dec 1986 A
4638800 Michel Jan 1987 A
4653495 Nanaumi Mar 1987 A
4656641 Scifres et al. Apr 1987 A
4662368 Hussein et al. May 1987 A
4677347 Nakamura Jun 1987 A
4686986 Fenyo et al. Aug 1987 A
4693244 Daikuzono Sep 1987 A
4693556 McCaughan, Jr. Sep 1987 A
4695697 Kosa Sep 1987 A
4710677 Halberstadt et al. Dec 1987 A
4718416 Nanaumi Jan 1988 A
4724835 Liss et al. Feb 1988 A
4733660 Itzkan Mar 1988 A
4735201 O'Reilly Apr 1988 A
4736743 Daikuzono Apr 1988 A
4736745 Gluckman Apr 1988 A
4740047 Abe et al. Apr 1988 A
4741338 Miyamae May 1988 A
4745909 Pelton et al. May 1988 A
4747660 Nishioka et al. May 1988 A
4749913 Stuermer et al. Jun 1988 A
4759349 Betz et al. Jul 1988 A
4773413 Hussein et al. Sep 1988 A
4775361 Jacques et al. Oct 1988 A
4779173 Carr et al. Oct 1988 A
4784135 Blum et al. Nov 1988 A
4799479 Spears Jan 1989 A
4813412 Yamazaki et al. Mar 1989 A
4813762 Leger et al. Mar 1989 A
4819669 Politzer Apr 1989 A
4826431 Fujimura et al. May 1989 A
4829262 Furumoto May 1989 A
4832024 Boussignac et al. May 1989 A
4840174 Gluckman Jun 1989 A
4840563 Altendorf Jun 1989 A
4845608 Gdula Jul 1989 A
4848339 Rink et al. Jul 1989 A
4852107 Hamal et al. Jul 1989 A
4852549 Mori Aug 1989 A
4860172 Schlager et al. Aug 1989 A
4860303 Russell Aug 1989 A
4860743 Abela Aug 1989 A
4860744 Johnson et al. Aug 1989 A
4862886 Clarke et al. Sep 1989 A
4862888 Yessik Sep 1989 A
4862903 Campbell Sep 1989 A
4871479 Bachelard et al. Oct 1989 A
4878224 Kuder Oct 1989 A
4884560 Kuracina Dec 1989 A
4887600 Watson et al. Dec 1989 A
4889525 Yuhas et al. Dec 1989 A
4890898 Bentley et al. Jan 1990 A
4891817 Duarte Jan 1990 A
4896329 Knaak Jan 1990 A
4898438 Mori Feb 1990 A
4898439 Mori Feb 1990 A
4901323 Hawkins et al. Feb 1990 A
4905690 Ohshiro et al. Mar 1990 A
4910438 Farnsworth Mar 1990 A
4913142 Kittrell et al. Apr 1990 A
4914298 Quad et al. Apr 1990 A
4917084 Sinofsky Apr 1990 A
4926227 Jensen May 1990 A
4928038 Nerone May 1990 A
4930504 Diamantopoulos Jun 1990 A
4931053 L'Esperance Jun 1990 A
4932954 Wondrazek et al. Jun 1990 A
4945239 Wist et al. Jul 1990 A
4950266 Sinofsky Aug 1990 A
4955882 Hakky Sep 1990 A
4968314 Michaels Nov 1990 A
4972427 Streifer et al. Nov 1990 A
4973848 Kolobanov et al. Nov 1990 A
4976308 Faghri Dec 1990 A
4976709 Sand Dec 1990 A
4977571 Furumoto et al. Dec 1990 A
4978186 Mori Dec 1990 A
4979180 Muncheryan Dec 1990 A
4992256 Skaggs et al. Feb 1991 A
4994060 Rink et al. Feb 1991 A
5000752 Hoskin et al. Mar 1991 A
5006293 Hartman et al. Apr 1991 A
5009658 Damgaard-Iversen Apr 1991 A
5011483 Sleister Apr 1991 A
5027359 Leger et al. Jun 1991 A
5030090 Maeda et al. Jul 1991 A
5032178 Cornell Jul 1991 A
5037421 Boutacoff et al. Aug 1991 A
5041109 Abela Aug 1991 A
5046494 Searfoss et al. Sep 1991 A
5050597 Daikuzono Sep 1991 A
5056515 Abel Oct 1991 A
5057099 Rink Oct 1991 A
5057104 Chess Oct 1991 A
5059192 Zaias Oct 1991 A
5060243 Eckert Oct 1991 A
5061266 Hakky Oct 1991 A
5065515 Iderosa Nov 1991 A
5066292 Müller et al. Nov 1991 A
5066293 Furumoto Nov 1991 A
5071416 Heller et al. Dec 1991 A
5071417 Sinofsky Dec 1991 A
5080660 Buelna Jan 1992 A
5090019 Scheps Feb 1992 A
5092865 Rink Mar 1992 A
5099231 Sato Mar 1992 A
5102410 Dressel Apr 1992 A
5108388 Trokel Apr 1992 A
5109387 Garden et al. Apr 1992 A
5112328 Taboada et al. May 1992 A
5127395 Bontemps Jul 1992 A
5129896 Hasson Jul 1992 A
5129897 Daikuzono Jul 1992 A
5132980 Connors et al. Jul 1992 A
5133102 Sakuma Jul 1992 A
5137530 Sand Aug 1992 A
5140608 Karpol et al. Aug 1992 A
5140984 Dew et al. Aug 1992 A
5147353 Everett Sep 1992 A
5147356 Bhatta Sep 1992 A
5151097 Daikuzono Sep 1992 A
5159601 Huber Oct 1992 A
5160194 Feldman Nov 1992 A
5163935 Black et al. Nov 1992 A
5171564 Nathoo et al. Dec 1992 A
5178617 Kuizenga et al. Jan 1993 A
5180378 Kung et al. Jan 1993 A
5182557 Lang Jan 1993 A
5182857 Simon Feb 1993 A
5190541 Abele et al. Mar 1993 A
5191883 Lennox et al. Mar 1993 A
5192278 Hayes et al. Mar 1993 A
5193526 Daikuzono Mar 1993 A
5196004 Sinofsky Mar 1993 A
5197470 Helfer et al. Mar 1993 A
5201731 Hakky Apr 1993 A
5207671 Franken et al. May 1993 A
5207672 Roth et al. May 1993 A
5207673 Ebling et al. May 1993 A
5209748 Daikuzono May 1993 A
5213092 Uram May 1993 A
5217455 Tan Jun 1993 A
5219347 Negus et al. Jun 1993 A
5222907 Katabuchi et al. Jun 1993 A
5222953 Dowlatshaki Jun 1993 A
5225926 Cuomo et al. Jul 1993 A
5226907 Tankovich Jul 1993 A
5242437 Everett et al. Sep 1993 A
5242438 Saadatmanesh Sep 1993 A
5246436 Rowe Sep 1993 A
5249192 Kuizenga et al. Sep 1993 A
5254114 Reed, Jr. et al. Oct 1993 A
5255277 Carvalho Oct 1993 A
5257970 Dougherty Nov 1993 A
5257991 Fletcher et al. Nov 1993 A
5261904 Baker et al. Nov 1993 A
5267399 Johnston Dec 1993 A
5267995 Doiron et al. Dec 1993 A
5267998 Hagen Dec 1993 A
5269777 Doiron et al. Dec 1993 A
5269780 Roos Dec 1993 A
5281211 Parel et al. Jan 1994 A
5281216 Klicek Jan 1994 A
5282797 Chess Feb 1994 A
5284154 Raymond et al. Feb 1994 A
5287372 Ortiz Feb 1994 A
5287380 Hsia Feb 1994 A
5290273 Tan Mar 1994 A
5290274 Levy et al. Mar 1994 A
5292320 Brown et al. Mar 1994 A
5293880 Levitt Mar 1994 A
5300063 Tano et al. Apr 1994 A
5300065 Anderson Apr 1994 A
5300097 Lerner et al. Apr 1994 A
5303585 Lichte Apr 1994 A
5304167 Freiberg Apr 1994 A
5304170 Green Apr 1994 A
5304173 Kittrell et al. Apr 1994 A
5306143 Levy Apr 1994 A
5306274 Long Apr 1994 A
5307369 Kimberlin Apr 1994 A
5308311 Eggers et al. May 1994 A
5312395 Tan et al. May 1994 A
5312396 Feld et al. May 1994 A
5320618 Gustafsson Jun 1994 A
5320620 Long et al. Jun 1994 A
5330470 Hagen Jul 1994 A
5331649 Dacquay et al. Jul 1994 A
5334191 Poppas et al. Aug 1994 A
5334193 Nardella Aug 1994 A
5336217 Buys et al. Aug 1994 A
5336221 Anderson Aug 1994 A
5342358 Daikuzono et al. Aug 1994 A
5344418 Ghaffari Sep 1994 A
5344434 Talmore Sep 1994 A
5346488 Prince et al. Sep 1994 A
5348551 Spears et al. Sep 1994 A
5349590 Amirkhanian et al. Sep 1994 A
5350376 Brown Sep 1994 A
5353020 Schurmann Oct 1994 A
5353790 Jacques et al. Oct 1994 A
5354294 Chou Oct 1994 A
5356081 Sellar Oct 1994 A
5358503 Bertwell et al. Oct 1994 A
5360426 Muller et al. Nov 1994 A
5366456 Rink et al. Nov 1994 A
5368031 Cline et al. Nov 1994 A
5368038 Fraden Nov 1994 A
5369496 Alfano et al. Nov 1994 A
5369831 Bock Dec 1994 A
5370642 Keller Dec 1994 A
5370649 Gardetto et al. Dec 1994 A
5380317 Everett et al. Jan 1995 A
5383876 Nardella Jan 1995 A
5386427 Zayhowski Jan 1995 A
5387211 Saadatmanesh Feb 1995 A
5395356 King et al. Mar 1995 A
5403306 Edwards et al. Apr 1995 A
5405368 Eckhouse Apr 1995 A
5409446 Rattner Apr 1995 A
5409479 Dew et al. Apr 1995 A
5409481 Poppas et al. Apr 1995 A
5415654 Daikuzono May 1995 A
5421337 Richards-Kortum Jun 1995 A
5421339 Ramanujam et al. Jun 1995 A
5422112 Williams Jun 1995 A
5423800 Ren et al. Jun 1995 A
5423803 Tankovich et al. Jun 1995 A
5423805 Brucker et al. Jun 1995 A
5425728 Tankovich Jun 1995 A
5425735 Rosen et al. Jun 1995 A
5425754 Braun et al. Jun 1995 A
5439954 Bush Aug 1995 A
5441499 Fritzsch Aug 1995 A
5445608 Chen et al. Aug 1995 A
5445611 Eppstein et al. Aug 1995 A
5454807 Lennox et al. Oct 1995 A
5456682 Edwards et al. Oct 1995 A
5458140 Eppstein et al. Oct 1995 A
5464436 Smith Nov 1995 A
5464724 Akiyama et al. Nov 1995 A
5470331 Daikuzono Nov 1995 A
5472748 Wolfe et al. Dec 1995 A
5474549 Ortiz et al. Dec 1995 A
5484436 Eggers et al. Jan 1996 A
5486170 Winston et al. Jan 1996 A
5486172 Chess Jan 1996 A
5488626 Heller et al. Jan 1996 A
5489256 Adair Feb 1996 A
5492894 Bascom et al. Feb 1996 A
5496305 Kittrell et al. Mar 1996 A
5496307 Daikuzono Mar 1996 A
5498935 McMahan et al. Mar 1996 A
5499313 Kleinerman Mar 1996 A
5501680 Kurtz et al. Mar 1996 A
5502582 Larson et al. Mar 1996 A
5505726 Meserol Apr 1996 A
5505727 Keller Apr 1996 A
5507739 Vassiliadis et al. Apr 1996 A
5519534 Smith et al. May 1996 A
5521367 Bard et al. May 1996 A
5522813 Trelles Jun 1996 A
5527350 Grove et al. Jun 1996 A
5527368 Supkis et al. Jun 1996 A
5530711 Scheps Jun 1996 A
5531739 Trelles Jul 1996 A
5531740 Black Jul 1996 A
5536168 Bourke Jul 1996 A
5540676 Freiberg Jul 1996 A
5540678 Long et al. Jul 1996 A
5540681 Strul et al. Jul 1996 A
5541948 Krupke et al. Jul 1996 A
5546214 Black et al. Aug 1996 A
5549660 Mendes et al. Aug 1996 A
5557625 Durville Sep 1996 A
5558666 Dewey et al. Sep 1996 A
5558667 Yarborough et al. Sep 1996 A
5561881 Klinger et al. Oct 1996 A
5571098 Domankevitz et al. Nov 1996 A
5578029 Trelles et al. Nov 1996 A
5578866 DePoorter et al. Nov 1996 A
5595568 Anderson et al. Jan 1997 A
5598426 Hsia et al. Jan 1997 A
5608210 Esparza et al. Mar 1997 A
5611793 Wilson et al. Mar 1997 A
5616140 Prescott Apr 1997 A
5618284 Sand Apr 1997 A
5620478 Eckhouse Apr 1997 A
5624435 Furumoto et al. Apr 1997 A
5626631 Eckhouse May 1997 A
5628744 Coleman et al. May 1997 A
5628771 Mizukawa et al. May 1997 A
5630811 Miller May 1997 A
5632741 Zavislan et al. May 1997 A
5634711 Kennedy et al. Jun 1997 A
5647866 Zaias et al. Jul 1997 A
5649972 Hochstein Jul 1997 A
5651783 Reynard Jul 1997 A
5652481 Johnson et al. Jul 1997 A
5653706 Zavislan et al. Aug 1997 A
5655547 Karni Aug 1997 A
5657760 Ying et al. Aug 1997 A
5658148 Neuberger et al. Aug 1997 A
5658323 Miller Aug 1997 A
5660836 Knowlton Aug 1997 A
5661744 Murakami et al. Aug 1997 A
5662643 Kung et al. Sep 1997 A
5662644 Swor Sep 1997 A
5668824 Furumoto Sep 1997 A
5671315 Tabuchi et al. Sep 1997 A
5673451 Moore et al. Oct 1997 A
5679113 Caisey et al. Oct 1997 A
5683380 Eckhouse et al. Nov 1997 A
5684902 Tada Nov 1997 A
5688266 Edwards et al. Nov 1997 A
5688267 Panescu et al. Nov 1997 A
5692509 Voss et al. Dec 1997 A
5698866 Doiron et al. Dec 1997 A
5707369 Vaitekunas et al. Jan 1998 A
5707401 Martin et al. Jan 1998 A
5707403 Grove et al. Jan 1998 A
5713738 Yarborough Feb 1998 A
5714119 Kawagoe et al. Feb 1998 A
5720772 Eckhouse Feb 1998 A
5722397 Eppstein Mar 1998 A
5725522 Sinofsky Mar 1998 A
5728090 Martin et al. Mar 1998 A
5735844 Anderson et al. Apr 1998 A
5735884 Thompson et al. Apr 1998 A
5738678 Patel Apr 1998 A
5742392 Anderson et al. Apr 1998 A
5743901 Grove et al. Apr 1998 A
5743902 Trost Apr 1998 A
5746735 Furumoto et al. May 1998 A
5748822 Miura et al. May 1998 A
5749868 Furumoto May 1998 A
5755751 Eckhouse May 1998 A
5759162 Oppelt et al. Jun 1998 A
5759200 Azar Jun 1998 A
5760362 Etoy Jun 1998 A
5769076 Maekawa et al. Jun 1998 A
5776129 Mersch Jul 1998 A
5782249 Weber et al. Jul 1998 A
5802136 Carol Sep 1998 A
5807386 Slatkine et al. Sep 1998 A
5810801 Anderson et al. Sep 1998 A
5810802 Panescu et al. Sep 1998 A
5812567 Jeon et al. Sep 1998 A
5813855 Crisio, Jr. Sep 1998 A
5814008 Chen et al. Sep 1998 A
5814040 Nelson et al. Sep 1998 A
5814041 Anderson et al. Sep 1998 A
5817089 Tankovich et al. Oct 1998 A
5818580 Murnick Oct 1998 A
5820625 Izawa et al. Oct 1998 A
5820626 Baumgardner Oct 1998 A
5822034 Shimashita et al. Oct 1998 A
5824023 Anderson Oct 1998 A
5827264 Hohla Oct 1998 A
5828803 Eckhouse Oct 1998 A
5830208 Muller Nov 1998 A
5830209 Savage et al. Nov 1998 A
5832931 Wachter Nov 1998 A
5835648 Narciso, Jr. Nov 1998 A
5836877 Zavislan Nov 1998 A
5836999 Eckhouse et al. Nov 1998 A
5837001 Mackey Nov 1998 A
5840048 Cheng Nov 1998 A
5843072 Furumoto et al. Dec 1998 A
5849029 Eckhouse et al. Dec 1998 A
5851181 Talmor Dec 1998 A
5853407 Miller Dec 1998 A
5860967 Zavislan et al. Jan 1999 A
5868731 Budnik et al. Feb 1999 A
5868732 Waldman et al. Feb 1999 A
5871479 Furumoto et al. Feb 1999 A
5871480 Tankovich Feb 1999 A
5879159 Cipolla Mar 1999 A
5879346 Waldman et al. Mar 1999 A
5879376 Miller Mar 1999 A
5883471 Rodman et al. Mar 1999 A
5885211 Eppstein et al. Mar 1999 A
5885273 Eckhouse et al. Mar 1999 A
5885274 Fullmer et al. Mar 1999 A
5891063 Vigil Apr 1999 A
5893828 Uram Apr 1999 A
5893885 Webster, Jr. Apr 1999 A
5895350 Hori Apr 1999 A
5897549 Tankovich Apr 1999 A
5906609 Assa et al. May 1999 A
5908418 Dority et al. Jun 1999 A
5908731 Leenders et al. Jun 1999 A
5913883 Alexander et al. Jun 1999 A
5916211 Quon et al. Jun 1999 A
5919601 Nguyen et al. Jul 1999 A
5920374 Vaphiades et al. Jul 1999 A
5921926 Rolland et al. Jul 1999 A
5928222 Kleinerman Jul 1999 A
5935124 Klumb et al. Aug 1999 A
5944687 Benett et al. Aug 1999 A
5944748 Mager et al. Aug 1999 A
5948011 Knowlton Sep 1999 A
5948596 Zhong et al. Sep 1999 A
5949222 Buono Sep 1999 A
5951543 Brauer Sep 1999 A
5954710 Paolini et al. Sep 1999 A
5955490 Kennedy et al. Sep 1999 A
5957915 Trost Sep 1999 A
5964749 Eckhouse et al. Oct 1999 A
5968033 Fuller et al. Oct 1999 A
5968034 Fullmer et al. Oct 1999 A
5971976 Wang et al. Oct 1999 A
5974059 Dawson Oct 1999 A
5974616 Dreyfus Nov 1999 A
5976123 Baumgardner et al. Nov 1999 A
5977723 Yoon Nov 1999 A
5979454 Anvari et al. Nov 1999 A
5983900 Clement et al. Nov 1999 A
5984915 Loeb et al. Nov 1999 A
6004723 Figov Dec 1999 A
6007219 O'Meara Dec 1999 A
6015404 Altshuler et al. Jan 2000 A
6017677 Maemoto et al. Jan 2000 A
6022316 Eppstein et al. Feb 2000 A
6022346 Panescu et al. Feb 2000 A
6024095 Stanley, III Feb 2000 A
6026828 Altshuler Feb 2000 A
6027493 Donitzky et al. Feb 2000 A
6027495 Miller Feb 2000 A
6028694 Schmidt Feb 2000 A
6029303 Dewan Feb 2000 A
6029304 Hulke et al. Feb 2000 A
6030378 Stewart Feb 2000 A
6030399 Ignotz et al. Feb 2000 A
6032071 Binder Feb 2000 A
RE36634 Ghaffari Mar 2000 E
6033431 Segal Mar 2000 A
6036684 Tankovich et al. Mar 2000 A
6044514 Kaneda et al. Apr 2000 A
6045548 Furumoto et al. Apr 2000 A
6050990 Tankovich et al. Apr 2000 A
D424197 Sydlowski et al. May 2000 S
6056548 Neuberger et al. May 2000 A
6056738 Marchitto et al. May 2000 A
6058937 Doiron et al. May 2000 A
6059820 Baronov May 2000 A
6063108 Salansky et al. May 2000 A
6068963 Aoshima May 2000 A
6070092 Kazama et al. May 2000 A
6071239 Cribbs et al. Jun 2000 A
6074382 Asah et al. Jun 2000 A
6077294 Cho et al. Jun 2000 A
6080146 Altshuler et al. Jun 2000 A
6080147 Tobinick Jun 2000 A
6083217 Tankovich Jul 2000 A
6086363 Moran et al. Jul 2000 A
6086558 Bower et al. Jul 2000 A
6086580 Mordon et al. Jul 2000 A
6090524 Deboer et al. Jul 2000 A
6132929 Nakamura Jul 2000 A
6094767 Iimura Aug 2000 A
6096028 Bahmanyar et al. Aug 2000 A
6096029 O'Donnell, Jr. Aug 2000 A
6096209 O'Brien et al. Aug 2000 A
6099521 Shadduck Aug 2000 A
6101207 Ilorinne Aug 2000 A
6104959 Spertell Aug 2000 A
6106293 Wiesel Aug 2000 A
6106294 Daniel Aug 2000 A
6110195 Xie et al. Aug 2000 A
6112123 Kelleher et al. Aug 2000 A
6113559 Klopotek Sep 2000 A
6117129 Mukai Sep 2000 A
6120497 Anderson et al. Sep 2000 A
6126655 Domankevitz et al. Oct 2000 A
6129723 Anderson Oct 2000 A
6135774 Hack et al. Oct 2000 A
6142650 Brown et al. Nov 2000 A
6142939 Eppstein et al. Nov 2000 A
6149644 Xie Nov 2000 A
6149895 Kutsch Nov 2000 A
6153352 Oohashi et al. Nov 2000 A
6159203 Sinofsky et al. Dec 2000 A
6159236 Biel Dec 2000 A
6162055 Montgomery et al. Dec 2000 A
6162211 Tankovich et al. Dec 2000 A
6162212 Kreindel et al. Dec 2000 A
6162215 Feng Dec 2000 A
6162218 Elbrecht et al. Dec 2000 A
6164837 Haake et al. Dec 2000 A
6171300 Adams Jan 2001 B1
6171301 Nelson Jan 2001 B1
6171302 Talpalriu et al. Jan 2001 B1
6171332 Whitehurst Jan 2001 B1
6173202 Eppstein Jan 2001 B1
6174325 Eckhouse Jan 2001 B1
6176854 Cone Jan 2001 B1
6177230 Kawamura Jan 2001 B1
6183434 Eppstein Feb 2001 B1
6183500 Kohler Feb 2001 B1
6183773 Anderson Feb 2001 B1
6187001 Azar et al. Feb 2001 B1
6187029 Shapiro et al. Feb 2001 B1
6190825 Denzinger et al. Feb 2001 B1
6190831 Leon et al. Feb 2001 B1
6197020 O'Donnell, Jr. Mar 2001 B1
6200134 Kovac et al. Mar 2001 B1
6200309 Rice et al. Mar 2001 B1
6202242 Salmon et al. Mar 2001 B1
6203540 Weber Mar 2001 B1
6210425 Chen Apr 2001 B1
6210426 Cho et al. Apr 2001 B1
6214034 Azar Apr 2001 B1
6221068 Fried et al. Apr 2001 B1
6221095 Van Zuylen et al. Apr 2001 B1
6228074 Almeida May 2001 B1
6228075 Furumoto May 2001 B1
6229831 Nightingale et al. May 2001 B1
6233584 Purcell et al. May 2001 B1
6235015 Mead et al. May 2001 B1
6235016 Stewart May 2001 B1
6236891 Ingle et al. May 2001 B1
6238839 Tomita et al. May 2001 B1
6239442 Iimura May 2001 B1
6240306 Rohrscheib et al. May 2001 B1
6240925 McMillan et al. Jun 2001 B1
6245093 Li et al. Jun 2001 B1
6245486 Teng Jun 2001 B1
6246710 Furumoto Jun 2001 B1
6246740 Maruyama et al. Jun 2001 B1
6248103 Tannenbaum et al. Jun 2001 B1
6248503 Vermeersch et al. Jun 2001 B1
6251127 Biel Jun 2001 B1
6254388 Yarborough Jul 2001 B1
6263233 Zavislan et al. Jul 2001 B1
6264649 Whitcroft et al. Jul 2001 B1
6267779 Gerdes Jul 2001 B1
6267780 Streeter Jul 2001 B1
6273883 Furumoto Aug 2001 B1
6273884 Altshuler et al. Aug 2001 B1
6273885 Koop et al. Aug 2001 B1
6280438 Eckhouse et al. Aug 2001 B1
6282442 Destefano et al. Aug 2001 B1
6283956 McDaniel Sep 2001 B1
6287549 Sumian et al. Sep 2001 B1
6290496 Azar et al. Sep 2001 B1
6290712 Nordquist et al. Sep 2001 B1
6290713 Russell Sep 2001 B1
6294311 Shimazu et al. Sep 2001 B1
6306130 Anderson et al. Oct 2001 B1
6306160 Nidetzky Oct 2001 B1
6315772 Marchitto et al. Nov 2001 B1
6317624 Kollias et al. Nov 2001 B1
6319274 Shadduck Nov 2001 B1
6322584 Ingle et al. Nov 2001 B2
6325769 Klopotek Dec 2001 B1
6327506 Yogo et al. Dec 2001 B1
6328733 Trost Dec 2001 B1
6331111 Cao Dec 2001 B1
6332891 Himes Dec 2001 B1
6338855 Albacarys et al. Jan 2002 B1
6340495 Sumian et al. Jan 2002 B1
6343400 Massholder et al. Feb 2002 B1
6343933 Montgomery et al. Feb 2002 B1
6346365 Kawauchi et al. Feb 2002 B1
6350261 Domankevitz et al. Feb 2002 B1
6350276 Knowlton Feb 2002 B1
6352811 Patel et al. Mar 2002 B1
6354370 Miller et al. Mar 2002 B1
6355054 Neuberger Mar 2002 B1
6358242 Cecchetti Mar 2002 B1
6358272 Wilden Mar 2002 B1
6358669 Savariar-Hauck et al. Mar 2002 B1
6364872 Hsia et al. Apr 2002 B1
6383176 Connors et al. May 2002 B1
6383177 Balle-Petersen May 2002 B1
6387089 Kreindel et al. May 2002 B1
6387353 Jensen et al. May 2002 B1
6391022 Furumoto et al. May 2002 B1
6394949 Crowley et al. May 2002 B1
6395016 Oron et al. May 2002 B1
6398801 Clement et al. Jun 2002 B1
6400011 Miki Jun 2002 B1
6402739 Neev Jun 2002 B1
6405732 Edwards et al. Jun 2002 B1
6406474 Neuberger et al. Jun 2002 B1
6409665 Scott et al. Jun 2002 B1
6409723 Edwards Jun 2002 B1
6413267 Dumoulin-White Jul 2002 B1
6416319 Cipolla Jul 2002 B1
6419389 Fuchs et al. Jul 2002 B1
6423462 Kunita Jul 2002 B1
6424852 Zavislan Jul 2002 B1
6425912 Knowlton Jul 2002 B1
6435873 Burgio Aug 2002 B1
6436094 Reuter Aug 2002 B1
6439888 Boutoussov et al. Aug 2002 B1
6440155 Matsumae et al. Aug 2002 B1
6440633 Kawauchi Aug 2002 B1
6443946 Clement et al. Sep 2002 B2
6443978 Zharov Sep 2002 B1
6447503 Wynne et al. Sep 2002 B1
6447504 Ben-Haim et al. Sep 2002 B1
6451007 Koop et al. Sep 2002 B1
6454790 Neuberger et al. Sep 2002 B1
6459919 Lys et al. Oct 2002 B1
6461296 Desai Oct 2002 B1
6464694 Massengill Oct 2002 B1
6468717 Kita et al. Oct 2002 B2
6470216 Mulholland Oct 2002 B1
6471712 Burres Oct 2002 B2
6471716 Pecukonis Oct 2002 B1
6475211 Chess et al. Nov 2002 B2
6482199 Neev Nov 2002 B1
6484052 Visuri et al. Nov 2002 B1
6485413 Boppart et al. Nov 2002 B1
6491685 Visuri et al. Dec 2002 B2
6493608 Niemeyer Dec 2002 B1
6494900 Salansky et al. Dec 2002 B1
6497702 Bernaz Dec 2002 B1
6503269 Nield et al. Jan 2003 B2
6503486 Xu et al. Jan 2003 B2
6508785 Eppstein Jan 2003 B1
6508813 Altshuler Jan 2003 B1
6511475 Altshuler et al. Jan 2003 B1
6514243 Eckhouse et al. Feb 2003 B1
6517532 Altshuler et al. Feb 2003 B1
6519376 Biagi et al. Feb 2003 B2
6525819 Delawter et al. Feb 2003 B1
6527716 Eppstein Mar 2003 B1
6527764 Neuberger et al. Mar 2003 B1
6529540 Demmer et al. Mar 2003 B1
6530915 Eppstein et al. Mar 2003 B1
6530916 Shimmick Mar 2003 B1
6537270 Elbrecht et al. Mar 2003 B1
6544257 Nagage et al. Apr 2003 B2
6547780 Sinofsky Apr 2003 B1
6551346 Crossley Apr 2003 B2
6554439 Teicher et al. Apr 2003 B1
6556596 Kim et al. Apr 2003 B1
6558372 Altshuler May 2003 B1
6561808 Neuberger May 2003 B2
6569155 Connors et al. May 2003 B1
6570892 Lin et al. May 2003 B1
6570893 Libatique et al. May 2003 B1
6572634 Koo Jun 2003 B2
6572637 Yamazaki et al. Jun 2003 B1
6595934 Hissong et al. Jul 2003 B1
6600951 Anderson Jul 2003 B1
6602245 Thiberg Aug 2003 B1
6602275 Sullivan Aug 2003 B1
6603988 Dowlatshahi Aug 2003 B2
6605080 Altshuler et al. Aug 2003 B1
6605083 Clement et al. Aug 2003 B2
6606755 Robinson et al. Aug 2003 B1
6607525 France et al. Aug 2003 B2
6610052 Furumoto Aug 2003 B2
6613040 Tankovich et al. Sep 2003 B2
6616447 Rizoiu et al. Sep 2003 B1
6616451 Rizoiu et al. Sep 2003 B1
6618531 Goto et al. Sep 2003 B1
6623272 Clemans Sep 2003 B2
6623513 Biel Sep 2003 B2
6629971 McDaniel Oct 2003 B2
6629989 Akita Oct 2003 B2
6632219 Baranov et al. Oct 2003 B1
6635075 Li et al. Oct 2003 B2
6641578 Mukai Nov 2003 B2
6641600 Kohler Nov 2003 B1
6648904 Altshuler et al. Nov 2003 B2
6652459 Payne et al. Nov 2003 B2
6653618 Zenzie Nov 2003 B2
6659999 Anderson et al. Dec 2003 B1
6660000 Neuberger et al. Dec 2003 B2
6663620 Altshuler et al. Dec 2003 B2
6663658 Kollias et al. Dec 2003 B1
6663659 McDaniel Dec 2003 B2
6666856 Connors et al. Dec 2003 B2
6669685 Rizoiu et al. Dec 2003 B1
6675425 Iimura Jan 2004 B1
6676654 Balle-Petersen Jan 2004 B1
6679837 Daikuzono Jan 2004 B2
6682523 Shadduck Jan 2004 B2
6682524 Elbrecht et al. Jan 2004 B1
6685639 Wang et al. Feb 2004 B1
6685699 Eppstein et al. Feb 2004 B1
6685722 Rosenbluth et al. Feb 2004 B1
6689124 Thiberg Feb 2004 B1
6692456 Eppstein et al. Feb 2004 B1
6692517 Cho et al. Feb 2004 B2
6699040 Hahn et al. Mar 2004 B1
6706035 Cense et al. Mar 2004 B2
6709269 Altshuler Mar 2004 B1
6709446 Lundahl et al. Mar 2004 B2
6723090 Altshuler et al. Apr 2004 B2
6724958 German et al. Apr 2004 B1
6726681 Grasso et al. Apr 2004 B2
6736807 Yamazaki et al. May 2004 B2
6743222 Durkin et al. Jun 2004 B2
6746444 Key Jun 2004 B2
6749623 Hsi et al. Jun 2004 B1
6755647 Melikechi et al. Jun 2004 B2
6770069 Hobart et al. Aug 2004 B1
6772053 Niemeyer Aug 2004 B2
6790205 Yamazaki et al. Sep 2004 B1
6800122 Anderson et al. Oct 2004 B2
6801595 Grodzins et al. Oct 2004 B2
6808331 Hall et al. Oct 2004 B2
6808532 Andersen et al. Oct 2004 B2
6824542 Jay Nov 2004 B2
RE38670 Asah et al. Dec 2004 E
6858009 Kawata et al. Feb 2005 B2
6860879 Irion et al. Mar 2005 B2
6860896 Leber et al. Mar 2005 B2
6862771 Muller Mar 2005 B1
6863781 Nocera et al. Mar 2005 B2
6872203 Shafirstein et al. Mar 2005 B2
6878144 Altshuler et al. Apr 2005 B2
6881212 Clement et al. Apr 2005 B1
6887260 McDaniel May 2005 B1
6888319 Inochkin et al. May 2005 B2
6893259 Reizenson May 2005 B1
6902397 Farrell et al. Jun 2005 B2
6902563 Wilkens et al. Jun 2005 B2
6905492 Zvuloni et al. Jun 2005 B2
6916316 Jay Jul 2005 B2
6917715 Berstis et al. Jul 2005 B2
6936046 Hissong et al. Aug 2005 B2
6942658 Rizoiu et al. Sep 2005 B1
6953341 Black Oct 2005 B2
6974450 Weber et al. Dec 2005 B2
6974451 Altshuler et al. Dec 2005 B2
6976985 Altshuler et al. Dec 2005 B2
6986903 Zulli et al. Jan 2006 B2
6989007 Shadduck Jan 2006 B2
6989023 Black Jan 2006 B2
6991644 Spooner et al. Jan 2006 B2
6997923 Anderson et al. Feb 2006 B2
7001413 Butler Feb 2006 B2
7006223 Mullani Feb 2006 B2
7006874 Knowlton Feb 2006 B2
7018196 Sierra et al. Mar 2006 B2
7029469 Vasily Apr 2006 B2
7033349 Key Apr 2006 B2
7041094 Connors et al. May 2006 B2
7041100 Kreindel May 2006 B2
7044959 Anderson et al. May 2006 B2
7060061 Altshuler et al. Jun 2006 B2
7066733 Logan et al. Jun 2006 B2
7070611 Biel Jul 2006 B2
7077840 Altshuler et al. Jul 2006 B2
7081128 Hart et al. Jul 2006 B2
7097639 Almeida Aug 2006 B1
7097656 Akopov et al. Aug 2006 B1
7104985 Martinelli Sep 2006 B2
7118562 Furumoto Oct 2006 B2
7118563 Weckwerth et al. Oct 2006 B2
7135033 Altshuler et al. Nov 2006 B2
7144247 Black Dec 2006 B2
7144248 Irwin Dec 2006 B2
7145105 Gaulard Dec 2006 B2
7145108 Kanel et al. Dec 2006 B2
7160289 Cohen Jan 2007 B2
7170034 Shalev Jan 2007 B2
7175617 Jay Feb 2007 B2
7182760 Kubota Feb 2007 B2
7198634 Harth et al. Apr 2007 B2
7202446 Shalev Apr 2007 B2
7204832 Altshuler et al. Apr 2007 B2
7216055 Horton et al. May 2007 B1
7217265 Hennings et al. May 2007 B2
7217267 Jay May 2007 B2
7220254 Altshuler et al. May 2007 B2
7223270 Altshuler et al. May 2007 B2
7223281 Altshuler et al. May 2007 B2
7255691 Tolkoff et al. Aug 2007 B2
7274155 Inochkin et al. Sep 2007 B2
7276058 Altshuler et al. Oct 2007 B2
7280866 McIntosh et al. Oct 2007 B1
7282060 DeBenedictis Oct 2007 B2
7282723 Schomaket et al. Oct 2007 B2
7291140 MacFarland et al. Nov 2007 B2
7291141 Harvey Nov 2007 B2
7309335 Altshuler et al. Dec 2007 B2
7311722 Larsen Dec 2007 B2
7322972 Viator et al. Jan 2008 B2
7329273 Altshuler et al. Feb 2008 B2
7329274 Altshuler et al. Feb 2008 B2
7331953 Manstein et al. Feb 2008 B2
7331964 Maricle et al. Feb 2008 B2
7333698 Israel Feb 2008 B2
7333841 Maruo et al. Feb 2008 B2
7351252 Altshuler et al. Apr 2008 B2
7354448 Altshuler et al. Apr 2008 B2
7422598 Altshuler et al. Sep 2008 B2
7423767 Steinsiek et al. Sep 2008 B2
7431719 Altshuler Oct 2008 B2
7436863 Matsuda et al. Oct 2008 B2
7500956 Wilk Mar 2009 B1
7531967 Inochkin et al. May 2009 B2
7540869 Altshuler et al. Jun 2009 B2
7553308 Jay Jun 2009 B2
7586957 Sierra et al. Sep 2009 B2
7588547 Deem et al. Sep 2009 B2
7624640 Maris et al. Dec 2009 B2
7647092 Motz et al. Jan 2010 B2
7699058 Jay Apr 2010 B1
7722600 Connors et al. May 2010 B2
7758621 Altshuler et al. Jul 2010 B2
7763016 Altshuler et al. Jul 2010 B2
7839972 Ruchala et al. Nov 2010 B2
7856985 Mirkov Dec 2010 B2
7860554 Leonardi Dec 2010 B2
7929579 Hohm et al. Apr 2011 B2
7931028 Jay Apr 2011 B2
7935107 Altshuler et al. May 2011 B2
7938821 Chan et al. May 2011 B2
7942869 Houbolt et al. May 2011 B2
7942915 Altshuler et al. May 2011 B2
7942916 Altshuler et al. May 2011 B2
7998181 Nightingale et al. Aug 2011 B2
8002768 Altshuler et al. Aug 2011 B1
8027710 Dannan Sep 2011 B1
8109924 Altshuler Feb 2012 B2
8113209 Masotti et al. Feb 2012 B2
8182473 Altshuler et al. May 2012 B2
8317779 Mirkov et al. Nov 2012 B2
8322348 Mirkov et al. Dec 2012 B2
8328794 Altshuler et al. Dec 2012 B2
8328796 Altshuler et al. Dec 2012 B2
8346347 Altshuler et al. Jan 2013 B2
8357145 Hennings et al. Jan 2013 B2
8378322 Dahm et al. Feb 2013 B2
8439940 Chomas et al. May 2013 B2
9028536 Sierra et al. May 2015 B2
9066736 Islam Jun 2015 B2
20010007068 Ota Jul 2001 A1
20010008973 Van Zuylen et al. Jul 2001 A1
20010016732 Hobart et al. Aug 2001 A1
20010023363 Harth et al. Sep 2001 A1
20010024777 Azar et al. Sep 2001 A1
20010025173 Ritchie et al. Sep 2001 A1
20010029956 Argenta et al. Oct 2001 A1
20010041886 Durkin et al. Nov 2001 A1
20010046652 Ostler et al. Nov 2001 A1
20010048077 Afanassieva Dec 2001 A1
20020002367 Tankovich et al. Jan 2002 A1
20020004066 Stanley et al. Jan 2002 A1
20020005475 Zenzie Jan 2002 A1
20020013572 Berlin Jan 2002 A1
20020015911 Nakamura Feb 2002 A1
20020016587 Furumoto Feb 2002 A1
20020018754 Sagel et al. Feb 2002 A1
20020019624 Clement et al. Feb 2002 A1
20020019625 Azar Feb 2002 A1
20020026225 Segal Feb 2002 A1
20020028404 Nakamura Mar 2002 A1
20020029071 Whitehurst Mar 2002 A1
20020032437 Andrews et al. Mar 2002 A1
20020039702 Hotta Apr 2002 A1
20020045891 Clement et al. Apr 2002 A1
20020048722 Aoshima Apr 2002 A1
20020049432 Mukai Apr 2002 A1
20020049483 Knowlton Apr 2002 A1
20020058890 Visuri et al. May 2002 A1
20020071287 Haase Jun 2002 A1
20020071827 Petersen et al. Jun 2002 A1
20020072676 Afanassieva Jun 2002 A1
20020081555 Wiesel Jun 2002 A1
20020090725 Simpson et al. Jul 2002 A1
20020091377 Anderson et al. Jul 2002 A1
20020108193 Gruber Aug 2002 A1
20020111546 Cook et al. Aug 2002 A1
20020111610 Nordquist Aug 2002 A1
20020120256 Furuno et al. Aug 2002 A1
20020123745 Svaasand et al. Sep 2002 A1
20020125230 Haight et al. Sep 2002 A1
20020127224 Chen Sep 2002 A1
20020128635 Altshuler et al. Sep 2002 A1
20020128695 Harth et al. Sep 2002 A1
20020128696 Pearl Sep 2002 A1
20020151878 Shimmick et al. Oct 2002 A1
20020151879 Loeb Oct 2002 A1
20020160299 Asawa et al. Oct 2002 A1
20020161357 Anderson et al. Oct 2002 A1
20020161418 Wilkens et al. Oct 2002 A1
20020167974 Kennedy et al. Nov 2002 A1
20020173723 Lewis Nov 2002 A1
20020173777 Sand Nov 2002 A1
20020173780 Altshuler et al. Nov 2002 A1
20020173781 Cense et al. Nov 2002 A1
20020173782 Cense et al. Nov 2002 A1
20020182563 Boutoussov et al. Dec 2002 A1
20020183808 Biel Dec 2002 A1
20020198517 Alfano et al. Dec 2002 A1
20030004499 McDaniel Jan 2003 A1
20030009158 Perricone Jan 2003 A1
20030009205 Biel Jan 2003 A1
20030018373 Eckhardt et al. Jan 2003 A1
20030023235 Cense et al. Jan 2003 A1
20030023283 McDaniel Jan 2003 A1
20030023284 Gartstein et al. Jan 2003 A1
20030028186 Kreintel Feb 2003 A1
20030028227 Neuberger et al. Feb 2003 A1
20030032900 Ella Feb 2003 A1
20030032950 Altshuler et al. Feb 2003 A1
20030036680 Black Feb 2003 A1
20030040739 Koop Feb 2003 A1
20030055413 Altshuler et al. Mar 2003 A1
20030055414 Altshuler et al. Mar 2003 A1
20030057875 Inochkin et al. Mar 2003 A1
20030059738 Neuberger Mar 2003 A1
20030065314 Altshuler et al. Apr 2003 A1
20030073989 Hoey et al. Apr 2003 A1
20030083649 Margaron et al. May 2003 A1
20030084534 Kaizuka May 2003 A1
20030092982 Eppstein May 2003 A1
20030097122 Ganz et al. May 2003 A1
20030100936 Altshuler et al. May 2003 A1
20030104340 Clemans Jun 2003 A1
20030109787 Black Jun 2003 A1
20030109860 Black Jun 2003 A1
20030113684 Scott Jun 2003 A1
20030129154 McDaniel Jul 2003 A1
20030130709 Haber Jul 2003 A1
20030152528 Singh et al. Aug 2003 A1
20030158550 Ganz et al. Aug 2003 A1
20030163884 Weihrauch Sep 2003 A1
20030167080 Hart et al. Sep 2003 A1
20030169433 Koele et al. Sep 2003 A1
20030181896 Zvuloni et al. Sep 2003 A1
20030187319 Kaneko Oct 2003 A1
20030187383 Weber et al. Oct 2003 A1
20030187486 Savage et al. Oct 2003 A1
20030195494 Altshuler et al. Oct 2003 A1
20030199859 Altshuler et al. Oct 2003 A1
20030216719 DeBenedictis Nov 2003 A1
20030216795 Harth et al. Nov 2003 A1
20030232303 Black Dec 2003 A1
20030233138 Spooner Dec 2003 A1
20040006332 Black Jan 2004 A1
20040010298 Altshuler et al. Jan 2004 A1
20040015156 Vasily Jan 2004 A1
20040015158 Chen et al. Jan 2004 A1
20040019120 Vargas et al. Jan 2004 A1
20040019990 Farrell et al. Feb 2004 A1
20040024388 Altshuler Feb 2004 A1
20040024430 Bader et al. Feb 2004 A1
20040030326 Altshuler et al. Feb 2004 A1
20040034319 Anderson et al. Feb 2004 A1
20040034341 Altshuler et al. Feb 2004 A1
20040036975 Slatkine Feb 2004 A1
20040054248 Kimchy et al. Mar 2004 A1
20040073079 Altshuler et al. Apr 2004 A1
20040082940 Black et al. Apr 2004 A1
20040085026 Inochkin et al. May 2004 A1
20040092506 Thompson et al. May 2004 A1
20040093042 Altshuler et al. May 2004 A1
20040093043 Edel et al. May 2004 A1
20040098070 Mohr et al. May 2004 A1
20040105611 Bischel et al. Jun 2004 A1
20040111031 Alfano et al. Jun 2004 A1
20040111086 Trombly Jun 2004 A1
20040111132 Shenderova et al. Jun 2004 A1
20040116984 Spooner et al. Jun 2004 A1
20040122311 Cosman Jun 2004 A1
20040133251 Altshuler et al. Jul 2004 A1
20040143181 Damasio et al. Jul 2004 A1
20040143247 Anderson et al. Jul 2004 A1
20040143920 Nanda Jul 2004 A1
20040147984 Altshuler et al. Jul 2004 A1
20040156626 Thoms Aug 2004 A1
20040161213 Lee Aug 2004 A1
20040162490 Soltz et al. Aug 2004 A1
20040162549 Altshuler Aug 2004 A1
20040162596 Altshuler et al. Aug 2004 A1
20040167502 Weckwerth et al. Aug 2004 A1
20040176754 Island et al. Sep 2004 A1
20040176764 Dant Sep 2004 A1
20040186465 Francischelli Sep 2004 A1
20040191729 Altshuler et al. Sep 2004 A1
20040193234 Butler Sep 2004 A1
20040193235 Altshuler et al. Sep 2004 A1
20040193236 Altshuler et al. Sep 2004 A1
20040199079 Chuck et al. Oct 2004 A1
20040199151 Neuberger Oct 2004 A1
20040199227 Altshuler et al. Oct 2004 A1
20040204745 Altshuler et al. Oct 2004 A1
20040208918 Koch et al. Oct 2004 A1
20040210275 Town et al. Oct 2004 A1
20040210276 Altshuler et al. Oct 2004 A1
20040214132 Altshuler Oct 2004 A1
20040225339 Yaroslavsky et al. Nov 2004 A1
20040230258 Altshuler et al. Nov 2004 A1
20040230260 MacFarland et al. Nov 2004 A1
20040234460 Tarver et al. Nov 2004 A1
20040249261 Torchia et al. Dec 2004 A1
20040260210 Ella et al. Dec 2004 A1
20050015077 Kuklin et al. Jan 2005 A1
20050038418 Altshuler et al. Feb 2005 A1
20050049467 Stamatas et al. Mar 2005 A1
20050049582 DeBenedictis et al. Mar 2005 A1
20050049658 Connors et al. Mar 2005 A1
20050063931 Paus et al. Mar 2005 A1
20050065502 Stoltz Mar 2005 A1
20050065531 Cohen Mar 2005 A1
20050074038 Khaydarov Apr 2005 A1
20050080404 Jones et al. Apr 2005 A1
20050085875 Van Zuylen Apr 2005 A1
20050102213 Savasoglu et al. May 2005 A1
20050107849 Altshuler et al. May 2005 A1
20050113815 Ritchie et al. May 2005 A1
20050113890 Ritchie et al. May 2005 A1
20050116673 Carl et al. Jun 2005 A1
20050131400 Hennings et al. Jun 2005 A1
20050143719 Sink Jun 2005 A1
20050143723 Zvuloni et al. Jun 2005 A1
20050154380 DeBenedictis Jul 2005 A1
20050165315 Zuluaga et al. Jul 2005 A1
20050165393 Eppstein Jul 2005 A1
20050168158 Inochkin et al. Aug 2005 A1
20050170313 Pitz et al. Aug 2005 A1
20050171517 Altshuler et al. Aug 2005 A1
20050171581 Connors et al. Aug 2005 A1
20050177026 Hoeg et al. Aug 2005 A1
20050177139 Yamazaki et al. Aug 2005 A1
20050177142 Jay Aug 2005 A1
20050182389 Laporte et al. Aug 2005 A1
20050197681 Barolet et al. Sep 2005 A1
20050203496 Ritchie et al. Sep 2005 A1
20050203497 Speeg et al. Sep 2005 A1
20050215988 Altshuler et al. Sep 2005 A1
20050220726 Pauly et al. Oct 2005 A1
20050222556 Arivra et al. Oct 2005 A1
20050245917 Strassl et al. Nov 2005 A1
20050251116 Steinke et al. Nov 2005 A1
20050251117 Anderson et al. Nov 2005 A1
20050251118 Anderson et al. Nov 2005 A1
20050251120 Anderson et al. Nov 2005 A1
20050257612 Hiemer et al. Nov 2005 A1
20050281530 Rizoiu et al. Dec 2005 A1
20060004306 Altshuler et al. Jan 2006 A1
20060004347 Altshuler et al. Jan 2006 A1
20060007965 Tankovich et al. Jan 2006 A1
20060009750 Altshuler et al. Jan 2006 A1
20060013533 Slatkine et al. Jan 2006 A1
20060020309 Altshuler et al. Jan 2006 A1
20060047281 Kreindel et al. Mar 2006 A1
20060052661 Gannot et al. Mar 2006 A1
20060056589 Engelward Mar 2006 A1
20060058712 Altshuler et al. Mar 2006 A1
20060062448 Hirsch et al. Mar 2006 A1
20060079947 Tankovich et al. Apr 2006 A1
20060089687 Spooner et al. Apr 2006 A1
20060094988 Tosaya et al. May 2006 A1
20060100677 Blumenkranz et al. May 2006 A1
20060116671 Slayton et al. Jun 2006 A1
20060118127 Chinn Jun 2006 A1
20060122584 Bommannan et al. Jun 2006 A1
20060122668 Anderson et al. Jun 2006 A1
20060128771 Mirkov et al. Jun 2006 A1
20060149343 Altshuler et al. Jul 2006 A1
20060155266 Manstein et al. Jul 2006 A1
20060161143 Altshuler et al. Jul 2006 A1
20060173480 Zhang Aug 2006 A1
20060194164 Altshuler et al. Aug 2006 A1
20060206103 Altshuler et al. Sep 2006 A1
20060217689 Dick et al. Sep 2006 A1
20060224148 Cho et al. Oct 2006 A1
20060247609 Mirkov et al. Nov 2006 A1
20060253176 Caruso et al. Nov 2006 A1
20060259102 Slatkine Nov 2006 A1
20060265032 Hennings Nov 2006 A1
20060271028 Altshuler et al. Nov 2006 A1
20060282067 Koop et al. Dec 2006 A1
20060287646 Altshuler et al. Dec 2006 A1
20060293727 Spooner et al. Dec 2006 A1
20060293728 Roersma et al. Dec 2006 A1
20070027440 Altshuler et al. Feb 2007 A1
20070038271 Cole et al. Feb 2007 A1
20070038206 Altshuler et al. Mar 2007 A1
20070049910 Altshuler et al. Mar 2007 A1
20070060819 Altshuler et al. Mar 2007 A1
20070060989 Deem et al. Mar 2007 A1
20070067006 Altshuler et al. Mar 2007 A1
20070073308 Anderson et al. Mar 2007 A1
20070078501 Altshuler et al. Apr 2007 A1
20070088206 Peyman Apr 2007 A1
20070093797 Chan et al. Apr 2007 A1
20070105212 Oldham et al. May 2007 A1
20070121069 Andersen et al. May 2007 A1
20070123851 Alejandro et al. May 2007 A1
20070142881 Hennings Jun 2007 A1
20070159592 Rylander et al. Jul 2007 A1
20070173749 Williams et al. Jul 2007 A1
20070179378 Boese et al. Aug 2007 A1
20070179470 Toombs Aug 2007 A1
20070185552 Masotti et al. Aug 2007 A1
20070191827 Lischinsky et al. Aug 2007 A1
20070194717 Belikov et al. Aug 2007 A1
20070197883 Zhou et al. Aug 2007 A1
20070198004 Altshuler et al. Aug 2007 A1
20070208252 Makower Sep 2007 A1
20070213696 Altshuler et al. Sep 2007 A1
20070213698 Altshuler et al. Sep 2007 A1
20070213792 Yaroslavsky et al. Sep 2007 A1
20070213851 Bellas et al. Sep 2007 A1
20070219602 Ostrovsky et al. Sep 2007 A1
20070219604 Yaroslavsky et al. Sep 2007 A1
20070219605 Yaroslavsky et al. Sep 2007 A1
20070239142 Altshuler et al. Oct 2007 A1
20070239143 Altshuler et al. Oct 2007 A1
20070244527 Hatayama et al. Oct 2007 A1
20070255355 Altshuler et al. Nov 2007 A1
20070260230 Youngquist et al. Nov 2007 A1
20070264625 DeBenedictis Nov 2007 A1
20070288071 Rogers et al. Dec 2007 A1
20080003536 Altshuler et al. Jan 2008 A1
20080004608 Dacquay et al. Jan 2008 A1
20080004611 Houbolt et al. Jan 2008 A1
20080009842 Manstein et al. Jan 2008 A1
20080031288 Sierra et al. Feb 2008 A1
20080033516 Altshuler et al. Feb 2008 A1
20080058782 Frangcischelli Mar 2008 A1
20080058783 Altshuler et al. Mar 2008 A1
20080082089 Jones et al. Apr 2008 A1
20080103565 Altshuler et al. May 2008 A1
20080132886 Cohen et al. Jun 2008 A1
20080139901 Altshuler et al. Jun 2008 A1
20080140164 Oberreiter et al. Jun 2008 A1
20080147054 Altshuler et al. Jun 2008 A1
20080154157 Altshuler et al. Jun 2008 A1
20080154247 Dallarosa Jun 2008 A1
20080172047 Altshuler et al. Jul 2008 A1
20080183162 Altshuler et al. Jul 2008 A1
20080183250 Tanojo et al. Jul 2008 A1
20080186591 Altshuler et al. Aug 2008 A1
20080194969 Werahera et al. Aug 2008 A1
20080195183 Botchkareva et al. Aug 2008 A1
20080208105 Zelickson et al. Aug 2008 A1
20080214988 Altshuler et al. Sep 2008 A1
20080215038 Bakker Sep 2008 A1
20080248554 Merchant et al. Oct 2008 A1
20080259969 Piper et al. Oct 2008 A1
20080262577 Altshuler et al. Oct 2008 A1
20080294150 Altshuler et al. Nov 2008 A1
20080294152 Altshuler et al. Nov 2008 A1
20080294153 Altshuler et al. Nov 2008 A1
20080306471 Altshuler et al. Dec 2008 A1
20080319430 Zenzie et al. Dec 2008 A1
20090014843 Kawashita et al. Jan 2009 A1
20090018531 Welches Jan 2009 A1
20090018624 Levinson et al. Jan 2009 A1
20090024023 Welches et al. Jan 2009 A1
20090024192 Knowlton Jan 2009 A1
20090024193 Altshuler et al. Jan 2009 A1
20090043294 Island et al. Feb 2009 A1
20090048557 Yeshurun et al. Feb 2009 A1
20090069741 Altshuler et al. Mar 2009 A1
20090132011 Altshuler et al. May 2009 A1
20090137995 Altshuler et al. May 2009 A1
20090149843 Smits et al. Jun 2009 A1
20090149844 Altshuler et al. Jun 2009 A1
20090222068 Oberreiter et al. Sep 2009 A1
20090227995 Bhawalkar et al. Sep 2009 A1
20090248004 Altshuler et al. Oct 2009 A1
20090254076 Altshuler et al. Oct 2009 A1
20090287195 Altshuler et al. Nov 2009 A1
20090292277 Sierra Nov 2009 A1
20090312749 Pini et al. Dec 2009 A1
20100010507 Kinoshita Jan 2010 A1
20100014543 Ogilvy et al. Jan 2010 A1
20100015576 Altshuler et al. Jan 2010 A1
20100021867 Altshuler et al. Jan 2010 A1
20100036295 Altshuler et al. Feb 2010 A1
20100049180 Wells et al. Feb 2010 A1
20100109041 Yin et al. May 2010 A1
20100123399 Bollmann et al. May 2010 A1
20100145321 Altshuler et al. Jun 2010 A1
20100195680 Sierra et al. Aug 2010 A1
20100198134 Eckhouse et al. Aug 2010 A1
20100204686 Yaroslavksy et al. Aug 2010 A1
20100217248 Mirkov et al. Aug 2010 A1
20100278756 Chung et al. Nov 2010 A1
20100286673 Altshuler et al. Nov 2010 A1
20100296531 Hohm et al. Nov 2010 A1
20100298744 Altshuler et al. Nov 2010 A1
20110046523 Altshuler et al. Feb 2011 A1
20110087155 Uhland et al. Apr 2011 A1
20110118722 Lischinsky et al. May 2011 A1
20110137230 Altshuler et al. Jun 2011 A1
20110152847 Mirkov et al. Jun 2011 A1
20110172651 Altshuler et al. Jul 2011 A1
20110182306 Hosseini et al. Jul 2011 A1
20110184334 Altshuler et al. Jul 2011 A1
20110207075 Altshuler et al. Aug 2011 A1
20110257584 Altshuler et al. Oct 2011 A1
20110267830 Altshuler et al. Nov 2011 A1
20110306956 Islam Dec 2011 A1
20110313408 Tankovich et al. Dec 2011 A1
20120022510 Welches et al. Jan 2012 A1
20120023129 Vedula et al. Jan 2012 A1
20120083862 Altshuler et al. Apr 2012 A1
20120099816 Wilson Apr 2012 A1
20120116271 Caruso et al. May 2012 A1
20120165725 Chomas et al. Jun 2012 A1
20120277659 Yaroslavsky et al. Nov 2012 A1
20120301842 Altshuler et al. Nov 2012 A1
20150180193 Sierra Jun 2015 A1
Foreign Referenced Citations (280)
Number Date Country
400305 Apr 1995 AT
1851583 Mar 1984 AU
2053926 Mar 1990 CN
1073607 Jun 1993 CN
1182572 May 1998 CN
1351483 May 2002 CN
1535126 Oct 2004 CN
2826383 Dec 1979 DE
3304230 Aug 1984 DE
8807746 Jan 1988 DE
3837248 May 1990 DE
3841503 Jun 1990 DE
9102407 Jul 1991 DE
3719561 Jan 1998 DE
19803460 Aug 1999 DE
19944401 Mar 2001 DE
10112289 Aug 2001 DE
10140715 Mar 2002 DE
10120787 Jan 2003 DE
0000593 Feb 1979 EP
0142671 May 1985 EP
0172490 Feb 1986 EP
0297360 Jan 1989 EP
0320080 Jun 1989 EP
0324120 Jul 1989 EP
0413025 Feb 1991 EP
0458576 Nov 1991 EP
0563953 Oct 1993 EP
0565331 Oct 1993 EP
0575274 Dec 1993 EP
0593375 Apr 1994 EP
0598984 Jun 1994 EP
0709941 May 1996 EP
0724894 Aug 1996 EP
0726083 Aug 1996 EP
0736308 Oct 1996 EP
0743029 Nov 1996 EP
0755698 Jan 1997 EP
0763371 Mar 1997 EP
0765673 Apr 1997 EP
0765674 Apr 1997 EP
0783904 Jul 1997 EP
0884066 Dec 1998 EP
0885629 Dec 1998 EP
0920840 Jun 1999 EP
0927544 Jul 1999 EP
1031414 Aug 2000 EP
1038505 Sep 2000 EP
1057455 Dec 2000 EP
1072402 Jan 2001 EP
1075854 Feb 2001 EP
1138269 Apr 2001 EP
1138349 Oct 2001 EP
1147785 Oct 2001 EP
1219258 Jul 2002 EP
1226787 Jul 2002 EP
1238683 Sep 2002 EP
1250893 Oct 2002 EP
1057454 Nov 2003 EP
1457234 Sep 2004 EP
1495735 Jan 2005 EP
1512373 Mar 2005 EP
1535582 Jun 2005 EP
1627662 Feb 2006 EP
1650615 Apr 2006 EP
1797836 Jun 2007 EP
1839705 Oct 2007 EP
1854505 Nov 2007 EP
2199453 Apr 1974 FR
2591902 Jun 1987 FR
1251424 Oct 1971 GB
1274017 May 1972 GB
1546625 May 1979 GB
2044908 Oct 1980 GB
2059053 Apr 1981 GB
2059054 Apr 1981 GB
2123287 Feb 1984 GB
2212010 Jul 1989 GB
2239675 Jul 1991 GB
2270159 Mar 1994 GB
2356570 May 2001 GB
2360461 Sep 2001 GB
2360946 Oct 2001 GB
2364376 Jan 2002 GB
2368020 Apr 2002 GB
2390021 Dec 2003 GB
2397528 Jul 2004 GB
S54129791 Oct 1979 JP
S5552766 Apr 1980 JP
S55577187 Jun 1980 JP
S574007 Jan 1982 JP
S62165985 Jul 1987 JP
S6323648 Jan 1988 JP
S63249577 Oct 1988 JP
S6427554 Jan 1989 JP
H0366387 Mar 1989 JP
S6481222 Mar 1989 JP
H01181877 Jul 1989 JP
H02199 Jan 1990 JP
H022199 Jan 1990 JP
H0213014 Jan 1990 JP
H0285694 Mar 1990 JP
H02174804 Jul 1990 JP
H02285694 Nov 1990 JP
H0319385 Jan 1991 JP
H0316956 Feb 1991 JP
H03183184 Aug 1991 JP
H03281390 Dec 1991 JP
H0622871 Feb 1994 JP
H06154239 Jun 1994 JP
H079179 Jan 1995 JP
H0763957 Mar 1995 JP
H07328025 Dec 1995 JP
H0815539 Jan 1996 JP
H0854538 Feb 1996 JP
H0984803 Mar 1997 JP
H09141869 Jun 1997 JP
H09220292 Aug 1997 JP
H1014661 Jan 1998 JP
H0199574 Apr 1998 JP
H1147146 Feb 1999 JP
H11232229 May 1999 JP
2000037400 Feb 2000 JP
2000153003 Jun 2000 JP
2000300684 Oct 2000 JP
2001000560 Jan 2001 JP
2001029124 Feb 2001 JP
2001145520 May 2001 JP
2001196665 Jul 2001 JP
2001343560 Dec 2001 JP
2002272861 Sep 2002 JP
2003052843 Feb 2003 JP
2005017796 Jan 2005 JP
2005027702 Feb 2005 JP
2006192073 Jul 2006 JP
2082337 Jun 1997 RU
2089126 Sep 1997 RU
2089127 Sep 1997 RU
2096051 Nov 1997 RU
2122848 Dec 1998 RU
WO 1986002783 May 1986 WO
WO 1996028212 Sep 1986 WO
WO 1988004592 Jun 1988 WO
WO 1990000420 Jan 1990 WO
WO 1990006727 Jun 1990 WO
WO 1990012548 Nov 1990 WO
WO 1991001053 Jan 1991 WO
WO 1991002562 Mar 1991 WO
WO 1991012050 Aug 1991 WO
WO 1991013652 Sep 1991 WO
WO 1991013653 Sep 1991 WO
WO 1991018646 Dec 1991 WO
WO 1992016338 Jan 1992 WO
WO 1992003977 Mar 1992 WO
WO 1992006739 Apr 1992 WO
WO 1992019165 Nov 1992 WO
WO 1993005920 Apr 1993 WO
WO 1993021843 Nov 1993 WO
WO 1995032441 Jan 1995 WO
WO 1995003089 Feb 1995 WO
WO 1995004393 Feb 1995 WO
WO 1995033518 Feb 1995 WO
WO 1995010243 Apr 1995 WO
WO 1995014251 May 1995 WO
WO 1995015725 Jun 1995 WO
WO 1996009853 Apr 1996 WO
WO 1996018347 Jun 1996 WO
WO 1996022741 Aug 1996 WO
WO 1996022813 Aug 1996 WO
WO 1996023447 Aug 1996 WO
WO 1996024182 Aug 1996 WO
WO 1996024406 Aug 1996 WO
WO 1996025979 Aug 1996 WO
WO 1996034316 Oct 1996 WO
WO 1996036396 Nov 1996 WO
WO 1996039734 Dec 1996 WO
WO 1996041579 Dec 1996 WO
WO 1997000777 Jan 1997 WO
WO 1997013458 Apr 1997 WO
WO 1997013552 Apr 1997 WO
WO 1997022384 Jun 1997 WO
WO 1997028752 Aug 1997 WO
WO 1997037602 Oct 1997 WO
WO 1997037723 Oct 1997 WO
WO 1998004317 Feb 1998 WO
WO 1998005286 Feb 1998 WO
WO 1998005380 Feb 1998 WO
WO 1998006456 Feb 1998 WO
WO 1998007379 Feb 1998 WO
WO 1998020937 May 1998 WO
WO 1998024507 Jun 1998 WO
WO 1998029134 Jul 1998 WO
WO 1998041158 Sep 1998 WO
WO 1998051235 Nov 1998 WO
WO 1998052481 Nov 1998 WO
WO 1998058595 Dec 1998 WO
WO 1999010046 Mar 1999 WO
WO 1999017666 Apr 1999 WO
WO 1999017667 Apr 1999 WO
WO 1999017668 Apr 1999 WO
WO 1999027997 Jun 1999 WO
WO 1999029243 Jun 1999 WO
WO 1999034867 Jul 1999 WO
WO 1999043387 Jul 1999 WO
WO 1999038569 Aug 1999 WO
WO 1999039410 Aug 1999 WO
WO 1999044638 Sep 1999 WO
WO 1999046005 Sep 1999 WO
WO 1999049937 Oct 1999 WO
WO 1999058195 Nov 1999 WO
WO 1999062472 Dec 1999 WO
WO 1999066988 Dec 1999 WO
WO 2000002491 Jan 2000 WO
WO 2000003257 Jan 2000 WO
WO 2000007514 Feb 2000 WO
WO 2000030714 Jun 2000 WO
WO 2000032272 Jun 2000 WO
WO 2000040266 Jul 2000 WO
WO 2000041278 Jul 2000 WO
WO 2000043070 Jul 2000 WO
WO 2000044294 Aug 2000 WO
WO 2000053113 Sep 2000 WO
WO 2000054649 Sep 2000 WO
WO 2000054685 Sep 2000 WO
WO 2000062700 Oct 2000 WO
WO 2000064537 Nov 2000 WO
WO 2000066226 Nov 2000 WO
WO 2000071045 Nov 2000 WO
WO 2000074583 Dec 2000 WO
WO 2000074781 Dec 2000 WO
WO 2000078242 Dec 2000 WO
WO 2001014012 Mar 2001 WO
WO 2001026573 Apr 2001 WO
WO 2001034048 May 2001 WO
WO 2001042671 Jun 2001 WO
WO 2001003257 Jul 2001 WO
WO 0161801 Aug 2001 WO
WO 2001054606 Aug 2001 WO
WO 2001054770 Aug 2001 WO
WO 2001078830 Oct 2001 WO
WO 2002009813 Feb 2002 WO
WO 2002026147 Apr 2002 WO
WO 2002053050 Jul 2002 WO
WO 2002069825 Sep 2002 WO
WO 2002078559 Oct 2002 WO
WO 2002094116 Nov 2002 WO
WO 2003005883 Jan 2003 WO
WO 2003049633 Jun 2003 WO
WO 2003103529 Dec 2003 WO
WO 2004000150 Dec 2003 WO
WO 2004011848 Feb 2004 WO
WO 2004033040 Apr 2004 WO
WO 2004037068 May 2004 WO
WO 2004037287 May 2004 WO
WO 2006089227 Aug 2004 WO
WO 2004073537 Sep 2004 WO
WO 2004080279 Sep 2004 WO
WO 2004084752 Oct 2004 WO
WO 2004086947 Oct 2004 WO
WO 2005007003 Jan 2005 WO
WO 2005009266 Feb 2005 WO
WO 2005030317 Apr 2005 WO
WO 2005046793 May 2005 WO
WO 2005065288 Jul 2005 WO
WO 2005092438 Oct 2005 WO
WO 2005096981 Oct 2005 WO
WO 2005099369 Oct 2005 WO
WO 2005112815 Dec 2005 WO
WO 2006006123 Jan 2006 WO
WO 2006036968 Apr 2006 WO
WO 2006066226 Jun 2006 WO
WO 2006101735 Sep 2006 WO
WO 2006116141 Nov 2006 WO
WO 2007035444 Mar 2007 WO
WO 2007122611 Nov 2007 WO
WO 2008007218 Jan 2008 WO
WO 2008070747 Jun 2008 WO
WO 2008153999 Dec 2008 WO
WO 2010102255 Sep 2010 WO
WO 2012023129 Feb 2012 WO
Non-Patent Literature Citations (231)
Entry
US 6,230,044 B1, 05/2001, Afanassieva et al. (withdrawn)
[No Author] Bioptron Light Therapy System. Website print-out, accessed Jul. 13, 2006 (2 pages).
[No Author] Derma Chiller advertisement (2 pages) from Paradigm Trex.
[No Author] IPG Data Sheet for TFL Thulium Laser, Jun. 2001.
[No Author] Webpage www.gallery.com—Rutile (Titanium Oxide)—Retrieved Oct. 3, 2011 from Http://www.galleries.com/minerals/oxides/rutile/rutile.htm. 2 pages.
[No Author] Altea Therapeutics—Medicines Made Better (single page website print-out, retrieved Sep. 30, 2004, © 2003-2004).
[No Author] Energy Systems Coropration, “A Practical Guide for the PhotoDern.RTM.VL user,” Haifa, Israel, Commercial Brochure 8 Pages, Oct. 1995.
[No Author] “Final Report on the LFDL-10 Laser System for the GCA Corporation,” Candela Corp., Natick, MA, Section II, subsection 5, pp. 13-15 & 27, Mar. 1982.
[No Author] “Fractional Photothermolysis Redefines Facial Skin Regeneration Science,” Aesthetic Buyers Guide, Mar./Apr. 2004, www.miinews.com, pp. 1-4.
[No Author] “Hydrogel Dressings Contain Particles During Laser Therapy,” Dermatology Times, ISSN-01966197, p. 26 (1994).
[No Author] “Instruction Manual, TFDL-10,” Adapted for SLAC, Candela Corporation, Natick, Oct. 1985.
[No Author] “Lasers Battle for Prostatectomy Market,” Medical Laser Industry Report, 5:1-3 (Aug. 1991).
[No Author] “LFDL-8 Instruction Manual,” Candela Laser Corporation, Wayland, MA Revised Oct. 1987.
[No Author] “LFDL-8 Instruction Manual,” Candela Laser Corporation, Wayland, MA, Jan. 1982, Revised Jun. 1987.
[No Author] “LFDL-8 Instruction Manual,” Cynosure, Inc., Bedford, MA, Revised Nov. 1992.
[No Author] “Prostate Enlargement: Benigh Prostatic Hyperplasia,” brochure from U.S. Department of Health and Human Services, pp. 1-14, (at least by 1992).
[No Author] “Special Instruction and Test Results for the LFDL-2 Wave Guide Laser,” Candela Laser Corporation, Wayland, MA, Sep. 1982.
[No Author] “The Laser TURP Advantage,” Intra-Sonix, Inc. pp. 1-4 (1991).
[No Author] Beckman Laser Institute “Experimental PDT to Prevent Esophegus Cancer,” (8 pages) 1996.
[No Author] Cynosure Dioderm 510(k) Notification K992765 for Cynosure, Inc. to Food and Drug Administration, dated: Aug. 16, 1999 and Aug. 20, 1999 (Additional Information).
[No Author] Reliant Technologies, Inc. “Physicians Guide: Understanding Faxel Laser Treatment,” pp. 1-10 (2004).
[No Author] Ritter Sybron Corporation, “Electrosurgery, A Guide for Operating Room Personnel,” pp. 1-22, (Jun. 1976).
[No Author] Selective Photothermolysis of Sebaceous Glands, Department of Health and Human Services, Public Health Service, Small Business Innovation Research Program II Grant Application, Cynosure, Inc., dated: Jul. 27, 2000, pp. 17-39 and 43-44.
[No Author] “Innovative Non-Surgical Treatment for Barrett's Esophagus”, Jul. 1995, see http:/www.plsgroup.com/dg950728.htm.
“American Society for Laser Medicine and Surgery Abstracts,” Lasers in Surgery and Medicine, Supplement 6, p. 46 (1994).
Anderson, R.R., et al., “Microvasculature Can Be Selectively Damaged Using Dye Lasers: A Basic Theory and Experimental Evidence in Human Skin,” Lasers in Surgery and Medicine 1:263-276 (1981).
Altshuler et al., “Human Tooth as an Optical Device,” SPIE vol. 1429 Holography and Interferometry and Optical Pattern Recognition in Biomedicine, pp. 95-104, 1991.
Altshuler et al., “Modern Optics and Dentistry,” Laser in Dentistry, pp. 283-297, 1995.
Altshuler et al., “New Optical Effects in the Human Hard Tooth Tissues,” Lasers and Medicine, Proc. SPIE vol. 1353, pp. 97-102, 1989.
Altshuler, et al., “Self Canalization of Laser Microbeam in Tissue as Fundamental Mechanism of Fractional Skin Resurfacing”, Lasers in Surgery and Medicine Supple 15, 21, 2003.
Altshuler, G.B. et al., “Acoustic response of hard dental tissues to pulsed laser action,” SPIE, vol. 2080, Dental Application of Lasers, pp. 97-103, 1993.
Altshuler, G.B. et al., “Extended theory of selective photothermolysis,” Lasers in Surgery and Medicine, vol. 29, pp. 416-432, 2001.
Amy, R.L. et al., “Selective mitochondrial damage by a ruby laser microbeam: An electron microscopic study,” Science, vol. 15, pp. 756-758, Nov. 1965.
Anderson, R.R. et al., “Selective photothermolysis: Precise microsurgery by selective absorption of pulsed radiation,” Science, vol. 220, pp. 524-527, Apr. 1983.
Anderson, R.R. et al., “The optics of human skin,” Journal of Investigative Dermatology, vol. 77, No. 1, pp. 13-19, 1981.
Ang et al., “Kalman Filtering for Real-Time Orientation Tracking of Handheld . . . ”, 2004 IEEE/RSJ Iner Conf on Intell Robots and Systems (IROS), Sendai, Japan.
Ang et al., “Design of All-Accelerometer Inertial Measurement Unit for Tremor Sensing in Hand-Held . . . ”, 2003 IEEE Inter Conf on Robotice and Automation (col. 2), Taipei, Taiwan.
Angelis, et al., “Fractional, Non-Ablative Laser Therapy for the Treatment of Striae Distensae”, White Paper published by Palomar Medical Technologies, Inc. (2009)5 pages.
Apfelberg et al. “Analysis of Complications of Argon Laser Treatment for Port Wine Hemangiomas with Reference to Striped Technique,” Lasers in Surgery and Medicine, 2:357-371 (1983).
Apfelberg et al. “Dot or Pointillistic Method for Improvement in Results of Hypertrophic Scarring in the Argon Laser Treatment of Portwine Hemangiomas,” Lasers in Surgery and Medicine, 6:552-558 (1987).
Apfelberg, D.B., “A Preliminary Study of the Combined Effect of Neodymium:YAG Laser Photocoagulation and Direct Steroid Instillation in the Treatment of Capillary/Cavemous Hemangiomas of Infancy,” Department of Plastic Surgery and Comprehensive Laser Center, Palo Alto Medical Foundation, Palo Alto, CA, pp. 94-103 (1989).
Apfelberg, D.B., “Combination Treatment for Massive Cavernous Hemangioma of the Face: YAG Laser Photocoagulation Pulse Direct Steroid Injection Followed by YAG Laser Resection with Sapphire Scalpel Tips, Aided by Superselective Embolization,” Lasers in Surgery and Medicine, 10:217-223 (1990).
Belikov, A.V. et al., “Identification of enamel and dentine under tooth laser treatment,” SPIE vol. 2623, Progress in Biomedical Optics Europt Series, Proceedings of Medical Applications of Lasers III, pp. 109-116, Sep. 1995.
Benjavitvilai, C. et al., “Fuzzy Calibration of Magnetometer in Presence of Surgical Microscope,” 2005 27th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (IEEE Cat. No. 05CH37811C), Shanghai, China, Aug. 31-Sep. 3, 2005.
Bjerring, P. et al., “Selective Non-Ablative Wrinkle Reduction by Laser,” J Cutan Laser Ther, vol. 2, pp. 9-15, 2000.
Blankenau et al., “In Vivo Caries-Like Lesion Prevention with Argon Laser: Pilot Study,” Journal of Clinical Laser Medicine and Surgery, vol. 17, No. 6, pp. 241-243, 1999.
Bogdan Allemann, et al., “Laser Principles”, Physical and Electronic Properties of Lasers, Basics in Dermatological Laser Applications, Curr. Probl. Dermatol, Basel, Karger. Zurich, Switzerland and Miami, Florida. vol. 42, pp. 7-23, 2011, 17 pages.
Bohm et al., “The Pilosebaceous Unit is Part of the Skin Immune System,” Dermatology, 196:75-79, 1998.
Boiteux, M., et al., “A Transverse Flow Repetitive Dye Laser,” Applied Optics, 9, 514 (1970).
Boulnois, J., “Photophysical Processes in Recent Medical Laser Developments: a Review,” Lasers in Medical Science, vol. 1:47-66 (1986).
Brauer, Jeremy A. et al., “Successful and Rapid Treatment of Blue and Green Tattoo Pigment With a Novel Picosecond Laser”, Archives of Dermatology, vol. 148, No. 7, 2012, pp. 820-823.
Britt et al., “The Effect of pH or Photobleaching of Organic Laser Dyes”, IEEE J. Quantum Electron. (Dec. 1972), 913-914.
Burlamacchi et al, “A Simple Reliable Waveguide Dye Laser for Ophthalmological Applications,” Rev of Sci Instrum; vol. 46; No. 3; pp. 281-283, Mar. 1975.
Chan, E.K., “Effects of Compression on Soft Tissue Optical Properties,” IEEE Journal of Selected Topics in Quantum Electronics, vol. 2, No. 4, pp. 943-950 (Dec. 1996).
Costello, A. et al., “Nd:YAG Laser Ablation of the Prostate as a Treatment for Benign Prostatic Hypertrophy,” Lasers in Surgery and Medicine, 12:121-124 (1992).
Cunliffe, “Acne Vulgaris. The Past, the Present and the Future,” Acta Bermatovener (Stockh) Suppl. 120, pp. 34-38, 1985.
Dabrowska, “Intravital Treatment of the Pulp with Stimulation Laser Biostimulation,” Abstract Rocz-Akad-Med-Bialymst. 1997; 42(1): 168-76.
Dierickx, C.C. et al., “Thermal Relaxation of Port-wine Stain Vessels Probed In Vivo: The Need for 1-10 Millisecond Laser Pulse Treatment,” The Journal for Investigative Dermatology, pp. 709-714 (1995).
Dixon et al. “Hypertrophic Scarring in Argon Laser Treatment of Port-Wine Stains,” Plastic and Reconstructive Surgery, 73:771-777 (1984).
Dock et al., “Clinical Histologic and Ultrastructural Evaluation of Solar Elastosis Treated With the Pulsed Dye Laser,” American Society for Laser Medicine and Surgery Abstracts, p. 54 (Apr. 1997).
Doukas et al., “Transdermal Drug Delivery With a Pressure Wave,” Advanced Drug Delivery Reviews 56 (2004), pp. 559-579.
Dover J.S. et al., “Pigmented guinea pig skin irradiated with Q-switched ruby laser pulses,” Arch Dermatol, vol. 125, pp. 43-49, Jan. 1989.
Dufresne et al., “Squamous cell carcinoma arising from the follicular occlusion triad,” J. Am. Acad. Dermatol. 35(3), Part 1:475-477, 1996.
Ellenberger, et al. “Single-Frequency Nd:Glass Laser Oscillator with Pulse-Transmission-Mode Q-Switch with Pulse-Transmission-Mode Q-Switch,” Optics communication, vol. 81, No. 6 (Mar. 1991).
Ertan et al., “Esophagel Adenocarcinoma Associated with Barrett's Esophagus: Long-term Management with Laser Ablation”, Am. J. Gastro, 90: pp. 2201-2203, 1995.
Fallon Friedlander, “Effective Treatment of Acne Fulminans-Associated Granulation Tissue with the Pulsed Dye Laser,” Pediatric Dermatology, 15(5):396-398, 1998.
Finkelstein L.H. et al., “Epilation of hair-bearing urethral grafts using the neodymium:yag surgical laser,” Journal of Urology, vol. 146, pp. 840-842, Sep. 1991.
Fiskerstrand E.J. et al., “Hair Removal with Long Pulsed Diode Lasers: A Comparison Between Two Systems with Different Pulse Structures,” Lasers in Surgery and Medicine, vol. 32, pp. 399-404, 2003.
Fletcher, A.N. et al., “Improving the Output and Lifetime of Flashlamp-Pumped Dye Lasers” Proceedings of the International Conference on Lasers '85, pp. 797-804, Dec. 2-6, 1985.
Forrest-Winchester et al., “The Effect of Infrared Laser Radiation on Dentinal Permeability in vitro,” Department of Dentistry, University of Queensland Dental School, pp. 1-8, 1992.
Friedman-Birnbaum et al., “Seborrheic Skin and Acne Vulgaris as Protective Factors against the Development of Basal Cell Epithelioma,” Dermatolgica, 183:160-163, 1991.
Furumoto, H., “Dye Chemistry and System Study for Optimum Laser Operation at 436 NM Using the LFDL-10 Laser,” Prepared for Burlington Division Geophysical Corporation of America, pp. 1-23, Mar. 1982.
Ginsbach et al. “New Aspects in the Management of Benign Cutameous Tumors.” Laser 79 Opto-Electronics, Munich Conference Proceedings, 344-347 (1979).
Goldberg, “Lasers for Facial Rejuvenation”, Am J. Clin, Dermatol., 4(4):225-234, 2003, 10 pages.
Goldberg, “Nonablative Resurfacing”, Clinics in Plastic Surgery, Skin Laser and Surgery Specialists of New York and New Jersey. Westwood, New Jersey. vol. 27, No. 2, Apr. 2000, 6 pages.
Goldman, L. et al. “Treatment of basal cell epithelioma by laser radiation,” JAMA, vol. 189, No. 10. pp. 773-775, 1964.
Goldman, L. et al., “Effect of the laser beam on the skin, III. Exposure of cytological preparations,” Journal of Investigative Dermatology, vol. 42, pp. 247-251, 1964.
Goldman, L. et al., “Effect of the laser beam on the skin, Preliminary report” Journal of Investigative Dermatology, vol. 40, pp. 121-122, 1963.
Goldman, L. et al., “Impact of the laser on nevi and melanomas,” Archives of Dermatology, vol. 90, pp. 71-75, Jul. 1964.
Goldman, L. et al., “Laser action at the cellular level,” JAMA, vol. 198, No. 6, pp. 641-644, Nov. 1966.
Goldman, L. et al., “Laser treatment of tattoos, A preliminary survey of three year's clinical experience,” JAMA, vol. 201, No. 11, pp. 841-844, Sep. 1967.
Goldman, L. et al., “Long-term laser exposure of a senile freckle,” ArchEnviron Health, vol. 22, pp. 401-403, Mar. 1971.
Goldman, L. et al., “Pathology, Pathology of the effect of the laser beam on the skin,” Nature, vol. 197, No. 4870, pp. 912-914, Mar. 1963.
Goldman, L. et al., “Preliminary Investigation of fat embolization from pulsed ruby laser impacts of bone,” Nature, vol. 221, pp. 361-363, Jan. 1969.
Goldman, L. et al., “Radiation from a Q-switched ruby laser, EffeCt of repeated impacts of power output of 10 megawatts on a tattoo of man,” Journal of Investigative Dermatology, vol. 44, pp. 69-71, 1965.
Goldman, L. et al., “Replica microscopy and scanning electron microscopy of laser impacts on the skin,” Journal of Investigative Dermatology, vol. 52, No. 1, pp. 18-24, 1969.
Goldman, L. et al., “The biomedical aspects of lasers,” JAMA, vol. 188, No. 3, pp. 302-306, Apr. 1964.
Goldman, L. et al., “The effect of repeated exposures to laser beams,” Acta derm.-vernereol., vol. 44, pp. 264-268, 1964.
Goldman, L., “Dermatologic manifestations of laser radiation,” Proceedings of the First Annual Conference on Biologic Effects of Laser Radiation, Federation of American Societies for Experimental Biology, Supp. No. 14, pp. S-92-S-93, Jan.-Feb. 1965.
Goldman, L., “Effects of new laser systems on the skin,” Arch Dermatol., vol. 108, pp. 385-390, Sep. 1973.
Goldman, L., “Laser surgery for skin cancer,” New York State Journal of Medicine, pp. 1897-1900, Oct. 1977.
Goldman, L., “Surgery by laser for malignant melanoma,” J. Dermatol. Surg. Oncol., vol. 5, No. 2, pp. 141-144, Feb. 1979.
Goldman, L., “The skin.” Arch Environ Health, vol. 18, pp. 434-436, Mar. 1969.
Goldman, L., Biomedical Aspects of the Laser, Springer-Verlag New York Inc., publishers, Chapts. 1, 2 & 23, 1967.
Goldman, M. P., “Leg Veins and Lasers,” American Society for Laser Medicine and Surgery Abstracts, Fourteen Annual Meeting, Toronto, Ontario, Canada, p. 48 (Apr. 8-10, 1994).
Goldman, M.P., “Sclerotherapy—Treatment of Varicose and Telangiectatic Leg Veins,” Second Edition, Mosby, pp. 454-467 (1995).
Gottlieb, I., “Power Supplies, Switching Regulators, Inverters & Converters,” 1976.
Greenwald et al. “Comparative Histological Studies of the Tunable Dye (at 577 nm) Laser and Argon Laser: The Specific Vascular Effects of the Dye Laser,” The Journal of Investigative Dermatology, 77:305-310 (1981).
Grossman, et al., “780 nm Low Power Diode Laser Irradiation Stimulates Proliferation of Keratinocyte Cultures: Involvement of Reactive Oxygen Species,” Lasers in Surgery and Medicine vol. 29, pp. 212-218, 1998.
Grossman, M.C. et al., “Damage to hair follicles by normal-mode ruby laser pulses,” Journal of he American Academy of Dermatology, vol. 35, No. 6, pp. 889-894, Dec. 1996.
Grossman, M.C. et al., “Laser Targeted at Hair Follicles,” Lasers Med Surg., Suppl. 13:221 (2001).
Habbema, Louis et al., “Minimally invasive non-thermal laser technology using laser-induced optical breakdown fir skin rejuvenation”, J. Biophotonics, vol. 5, No. 2, 2012, pp. 194-199.
Haedersal, et el., “Fractional Nonablative 1540 nm Laser Resurfacing for Thermal Bum Scars: A Randomized Controlled Trial”, Lasers in Surgery and Medicine, 41:189-195, 2009, 7 pages.
Hicks et al., “After Low Fluence Argon Laser and Flouride Treatment,” Compendium, vol. 18, No. 6, Jun. 1997.
Hicks et al., “Enamel Carries Initiation and Progression Following Low Fluence (energy) and Argon Laser and Fluoride Treatment,” The Journal of Clinical Pediatric Dentistry, vol. 20, No. 1 pp. 9-13, 1995.
Hsu et al., “Combined Effects of Laser Irradiation/Solution Flouride Ion on Enamel Demineralization,” Journal of Clinical Laser Medicine and Surgery, vol. 16, No. 2 pp. 93-105, 1998.
Hulsbergen Henning et al. “Clinical and Histological Evaluation of Portwine Stain Treatment with a Microsecond-Pulsed Dye-Laser at 577 NM,” Lasers in Surgery and Medicine, 4:375-380 (1984).
Hulsbergen Henning et al., “Port Wine Stain Coagulation Experiments with a 540-nm Continuous Wave Dye-Laser,” Lasers in Surgery and Medicine, 2:205-210 (1983).
Invention description to certificate of authorship, No. 719439, “The ring resonator of optical quantum generator” (Aug. 15, 1975).
Invention description to certificate of authorship, No. 741747, “The modulator of optical radiation intensity” (Oct. 10, 1977).
Invention description to certificate of authorship, No. SU 1257475 A1, “Laser interferometric device to determine no-linearity of an index of refraction of optical medium” (Sep. 15, 1986).
Invention description to certificate of authorship, No. SU 1326962 A1, “The way of determination of non-linearity of an index of refraction of optical medium” (Jul. 30, 1987).
Invention description to certificate of autorship, No. 532304, “The way of investigation of radiation time structure of optical quantum generator” (Jul. 9, 1974).
Ivanov, A.P. et al., “Radiation Propagation in Tissues and Liquids with Close Particle Packing,” Zhurnal Prikladnoi Spektroskopii, vol. 47, No. 4, pp. 682-668 (Oct. 1987).
Johnsson et al., “No photoinactivation of Propionibacterium acnes with soft laser treatment,” Dermatologica, 175(1):50, 1987.
Kalivradzhiyan et al., “The Usage of Low Intensity Laser Radiation for the Treatment of the Inflammatory processes of the Oral Cavity Mucosa after Applying Removable Plate Dentures,” SPIE vol. 1984 pp. 225-230.
Kandel, Laurence B., M.D., et al., “Transurethral Laser Prostatectomy in the Canine Model,” Lasers in Surgery and Medicine, 12:33-42 (1992).
Kantor et al., “Treatment of acne keloidalis nuchae with carbon dioxide laser,” J. Am. Acad. Dermatol., 14:263-267, 1986.
Karu, “Cell Attachment to Extracellular Matrics is Modulated by Pulsed Radiation at 820 nm and Chemicals that Modify the Activity of Enzymes in the Plasma Membrane,” Laser in Surgery and Medicine, vol. 29, pp. 274-281, 2001.
Karu, “Photobiological Fundamentals of Low-Power Laser Therapy,” 8th Congress of International Society for Laser Surgery and Medicine, Mar. 30, 1987.
Kazmina et al., “Laser Prophiaxis and Treatment of Primary caries,” SPIE vol. 1984, pp. 231-233.
Kelly et al., “Nonablative Laser Treatment of Facial Rhytides: United States Phase II Clinical Study,” American Society for Laser Medicine and Surgery Abstracts, 10(33):38 (1998).
Kilmer et al., “Pulse Dye Laser Treatment of Rhytids,” American Society for Laser Medicine and Surgery Abstracts, p. 44 (Apr. 1997).
Klein, E. et al., “Biological effects of laser radiation 1.,”Northeast Electroncis Research and Engineering Meeting, NEREM Record, IEEE catalogue No. F-60, pp. 108-109, 1965.
Kliewer, Michael L. et al., “Excited State Absorption of Pump Radiation as a Loss Mechanism in Solid-State Lasers”, IEEE Journal of Quantum Electronics, vol. 25, 1989, pp. 1850-1854.
Korobov et al., “Dependence of the Quantum Yield of Intercombinational Conversion into the Triplet State of Rhodamine 6G on the pH of the Medium”, Zhur. Prikl. Spektrosk. 24(1) 28-31 (Jan. 1976).
Kozlov et al., “Laser in Diagnostics and Treatment of Microcirculation Disorders Under Parodontitis,” SPIE vol. 1984, pp. 253-264.
Krames et al. “Status and Future of High-Power Light-Emitting Diodes for Solid State Lighting”, J. Display Technol., 3(2):160-175 (Jun. 2007).
Kuhns, J.G. et al., “Biological effects of laser radiation II Effects of laser irradiation on the skin,” NEREM Record, pp. 152-153, 1965.
Kuhns J.G. et al., “Laser injury in skin,” Laboratory Investigation, vol. 17, No. 1, pp. 1-13, Jul. 1967.
Kuizenga, Dirk J. et al., “FM and AM Mode Locing of the Homogenous Laser-Part I: Theory”, IEEE Journal of Quantum Electronics, vo. 6, No. 11, Nov. 1970, pp. 694-708.
Lee, Junsu et al., “Q-switched Mode-Locking of an Erbium-doped Fiber Laser through Subharmonic Cavity Modulation”, Photonics Conference (IPC), 202 IEEE, Sep. 23, 2012, pp. 664-665.
Leger, J. et al., “Geometrical Transformation of Linear Diode-Laser Arrays for Longitudinal Pumping of Solid-State Lasers”, IEEE Journal of Quantum Electronics, vol. 28, No. 4, Apr. 1992.
Lesnik et al., “Agents that cause enlargement of sebaceous glands in hairless mice,” Arch. Dermatol., 284:100-105, 1992.
Levin, G. et al., “Designing with hyseretic current-mode control,” EDN Magazine, pp. 1-8, Apr. 11, 1996.
Levin, G. et al., “Designing with hyseretic current-mode control,” EDN Magazine, pp. 1-8, Apr. 28, 1994.
Lucchina et al., “Fluorescence photography in the evaluation of acne,” J. Am. Acad. Dermatol. 35:58-63 (1996).
Maegawa, et al., “Effects of Near-Infrared Low-Level Laser Irradiation on Microcirculation,” Lasers in Surgery and Medicine, vol. 27, pp. 427-437, 2000.
Mamedova et al., “Microbiological Estimate of Parodontis Laser Therapy Efficiency,” SPIE vol. 1984, pp. 247-249.
Mang, “Effect of Soft Laser Treatment on Wound Healing in the Hamster Oral Mucosa,” Lasers in Surgery and Medicine, Supp. 8, Abstracts, Abstract 25, 1996.
Manstein, D. et al., “Selective Photothermolysis of Lipid-Rich Tissue,” American Society for Laser medicine and Surgery Abstracts, No. 17, American Society for Laser Medicine and Surgery Twenty-First Annual Meeting, Apr. 20-22, 2001, p. 6.
Manstein, D., et al., “Fractional Photothermolysis: A New Concept for Cutaneous Remodeling Using Microscopic Patterns of Thermal Injury,” Lasers in Surgery and Medicine, 34: 426-438 (2004).
Manuskiatti et al., “Laser hair removal affects sebaceous glands and sebum excretion . . . ,” J. Am. Acad. Dermatol., 41:176-180, 1999.
Margolis, R.J. et al., “Visible action spectrum for melanin-specific selective photothermolysis,” Lasers in Surgery and Medicine, vol. 9, pp. 389-397, 1989.
Marinelli et al., “Diode laser illuminated automotive lamp systems,” SPIE Proceedings vol. 3285:170-177 (1998).
Marshak, I.S., et al., “Pulsed Light Sources,” State Power Engineering Press, Moscow and Leningrad (1963).
Matsunaga et al., “Effect of pH on Dye-Laser Output Power”, J. Appl. Phys. 48(2):842-844 (Feb. 1977).
McCullough, David L., M.D., “Transurethral Laser Treatment of Benign Prostatic Hyperplasia,” and “Transurethral Ultrasound-guided Laser-Induced Prostatectomy (TULIP) Procedure): A Canine Prostate Feasibility Study,” by Roth, Robert A., M.D., et al., The Journal of Urology, 146:1126-1135 (1991).
McDaniel, et al., “Hexascan: A New Robotized Scanning Laser Handpiece,” Cutis, 45:300-305 (1990).
McNicholas, T. A., et al., “Interstitial Laser Coagulation of the Prostate: Experimental Studies,” SPIE, 1421:30-35 (1991). (From Proceedings of Lasers in Urol., Laparoscopy, and General Surgery, Jan. 21-23, 1991).
Mingxin, Qiu et al., “Performance of a Nd:YVO4 microchip laser with continuous-wave pumping at wavelengths between 741 and 825 nm”, Applied Optics, vol. 32, No. 12, Apr. 20, 1993, p. 2085.
Moretti, Michael, “Holmium Boosts Orthopedic Laser Development,” Medical Laser Buyers Guide, p. 93 (1992).
Moretti, Michael, “Lasers Improve Prostatectomy Treatment,” Medical Laser Buyers Guide. p. 94-96 (1992).
Mostovnikov, V.A. et al., “Recovery of Lasing Properties of Dye Solutions after Their Photolysis,” Sov. J. Quantum Electron, 6(9), Sep. 1976, pp. 1126-1128.
Nanni, C.A. et al., “Complications of Carbon Dioxide Laser Resurfacing,” Washington Inst. of Dermatol. Surg. 24:315-320 (1998).
Nemeth, et al., “Copper vapor laser treatment of pigmented lesions,” Lasers Surg. Med. Supp. 2:51 (1990).
Ogiso et al, “Phase Transitions of Rat Stratum Corneum Lipids by an Electron Paramagnetic Resonance Study and Relationship of Phase States to Drug Penetration,” Biochimica et Biophysica Acta 1301:97-104 (1996).
Ohbayashi, “Stimulatory Effect of Laser Irradiation an Calcified Nodule Formation in Human Dental Pulp Fibroblasts,” Abstract J-Endod. Jan. 1999: 25(1): 30-3.
Ohshiro et al., “The Ruby and Argon Lasers in the Treatment of the Naevi,” Annals Academy of Medicine, Apr. 1983, vol. 12, No. 2, pp. 388-395.
Oleinik, et al., “Automatized Securing Definition for Laser Therapy Indications in Case of Non-complicated Caries,” SPIE, vol. 1984, pp. 238-244.
Oraevsky, Alexander A. et al., “Plasma Mediated Ablation of Biological Tissues with Nanosecond-to-Femtosecond Laser Pulses: Relative Role of Lineear and Nonlinear Absorption”, IEEE Journal of Selected Topics in Quantum Electronics, vol. 2, No. 4, Dec. 1996, pp. 801-809.
Orchardson, “Effect of Pulsed Nd:YAG Laser Radiation on Action Potential Conduction in Nerve Fibres Inside Teeth in vitro,” Abstract J-Dent. Jul.-Aug. 1998; 26(5-6): 421-6.
Overholt BF et al. “Balloon photodynamic therapy of esophageal cancer: effect of increasing balloon size.” PubMed; Lasers Surg Med. 1996, 18(3):248-52.
Ozawa et al., “Stimulatory Effects of Low-Power Laser Irradiation on Bone Formation in vitro,” SPIE vol. 1984, pp. 281-288.
Panjehpour M et al. “Spectroscopic diagnosis of esophageal cancer: new classification model, improved measurement system.” PubMed; Gastrointest Endosc. Jun. 1995; 41 (6):577-81.
Parrish, J.A., “Selective thermal effects with pulsed irradiation from lasers: From organ to organelle,” Journal of investigative Dermatology, vol. 80, No. 6 Supplement, pp. 75s-80s, 1983.
Petrischev et al. “Clinical and Experimental Low-Intense Laser Therapy in Dentistry,” SPIE, vol. 1984, pp. 212-214.
Petrischev et al., “Report on Low Intensity Laser Radiation Usage in Dentistry,” SPIE vol. 1984, pp. 202-211.
Polanyi, Thomas & Tobias, Irwin, Lasers-A Series of Advances, Edited by A.K. Levine, vol. 2, Marcel Dekker, Inc, N.Y., 1968, pp. 400, 402-403 & 422.
Polla, L. et al., “Melanosomes are a primary target of Q-switched ruby laser irradiation in guinea pig skin,” Journal of Investigative Dermatology, vol. 89, No. 3, pp. 281-286, Sep. 1987.
Powell, “Laser Dental Decay Prevention: does it have a future?” SPIE vol. 3192, 1997.
Reed J.T. et al., “Treatment of Periorbital Wrinkles,” Washington Inst. of Dermatol. Surg. 23:643-648 (1997).
Remillard et al., “Diode laser illuminated automotive brake lamp using a linear fanout diffractive optical element,” Proc. of the Diffractive Optics and Micro-Optics Conference, OSA Technical Digest Series vol. 10, 192-194 (1998).
Remillard et al., “Diode Laser illuminators for Night-Vision Applications,” SPIE Proceedings vol. 4285:14-22 (2001).
Riggle et al., “Laser Effects on Normal and Tumor Tissue,” Laser Applications in Medicine and Biology, vol. 1, M.L Wolbarsht, editor, Plenum Press, publishers, Ch. 3, pp. 35-65 (1971).
Rohrer, “Evaluating the Safety and Efficacy of a Novel Light Based Hair Removal System,” Lasers. Surg. Med. Supp.13:97 (2001).
Rosenfeld, H., et al., “Treatment of Cutaneous and Deep Vascular Lesions with the Nd:YAG Laser,” Lasers in Surgery and Medicine, 6:20-23 (1986).
Rotteleur, et al., “Robotized scanning laser handpiece for the treatment of port wine stains and other angiodysplasias,” Lasers Surg. Med., 8:283-287 (1998).
Rubach et al., “Histological and Clinical Evaluation of Facial Resurfacing Using a Carbon Dioxide Laser With the Computer Pattern Generator,” Arch Otolaryngol Head Neck Surg., 123:929-934 (1997).
Russel et al. “Flash-Lamp-Excited Self-Injection-Seeded Q-Switch Ti:Al2O3 Laser Oscillator,” Applied Optics, vol. 35, No. 24 (Aug. 1996).
Rylander, C.G. et al., “Mechanical Tissue Optical Clearing Devices: Enhancement of Light Penetration in Ex Vivo Porcine Skin and Adipose Tissue,” Lasers in Surgery and Medicine, vol. 40, pp. 688-694 (2008).
Sandford et al., “Thermal Effects During Desensitisation of Teeth with Gallium-Aluminum-Arsenide Lasers,” University of Queensland Dental School, Periodontology 15: 25-30 (1994).
Schade, W. et al., “Temperature tuned distributed feedback dye laser with high repetition rate”, Applied Optics, vol. 2 9, No. 27, Sep. 20, 1990, pp. 3950-3954.
Schappert et al., “Temperture Tuning of an Organic Dye Laser” Applied Physics Letters 13(4):124-126 (Aug. 15, 1968).
Schindl, “Does Low Intensity Laser Irradiation Really Cause Cell Damage?” Laser in Surgery and Medicine vol. 22, pp. 105, 2001.
Sheehan-Dare, et al., “Lasers in Dermatology,” British Journal of Dermatology, 129:1-8 (1993).
Shimbashi, T. et al., “Ruby laser treatment of pigmented skin lesions,” Aesth. Plast. Surg., vol. 19, pp. 225-229, 1995.
Shimizu et al., “Prospect of Relieving Pain Due to Tooth Movement During Orthodontic Treatment Utilizing a GA-AI as Diode Laser,” SPIE vol. 1984, pp. 275-280.
Shumilovitch et at., “Influence of Low Intensity Laser Radiation Upon the Microflora of Carious Cavities and Root Canal,” SPIE vol. 1984, pp. 215-220.
Shuster, “Acne: The Ashes of a Burnt Out Controversy,” Acta Derm. Venereol. Suppl. (Stockh), 120:43-46, 1985.
Sigurdsson et al., “Phototherapy of Acne Vulgaris with Visible Light,” Dermatology, 194:256-260, 1997.
Sing, “Electroacupuncture and Laser Stimulation Treatment: Evaluation by Somatosensory Evoked Potential in Conscious Rabbits,” Abstract AM-J-Chin-Med. 1997; 25(3-4): 263-71.
Suney et al., “Safety with Lasers and Other Optical Sources: A Comprehensive Handbook,” Plenum Press, pp. 477-480 (1980).
Sokolova et al., “Low-Intense Laser Radiation in Complex Treatment of Inflammatory Diseases of Parodontium,” SPIE vol. 1984, pp. 234-237.
Spears et al., “Fluorescence of Experimental Atheromatous Plaques with Hematoporphyrin Derivative,” J. Clin. Invest, 71:395-399 (1983).
Spotswood, “Novel Use of Fractional Lasers for Scarring Improves Quality of Life for Injured Troops”, http://www.usmedicine.com/articles/novel-use-of-fractional-lasers-for-scarring-improves-quality-of-life-for-injured-troops-.html, (Aug. 2012) , U.S. Medicine ISSN: 0191-6246. 4 pages.
Stratton, K. et al., “Biological Effects of Laser Radiation Ii: ESR Studies of Melanin Containing Tissues after Laser Irradiation,” Northeast Electronics Research and Engineering Meeting—NEREM Record, IEEE Catalogue No. F-60, pp. 150-151, Nov. 1965.
Strauss et al., “Skin Lipids and Acne,” Annu. Rev. Med., 26: 27-31, 1975.
Sumian, C.C. et al., “A Preliminary Clinical and Histopathological Study of Laser Skin Resurfacing Using a frequency-Doubled Nd:YAG Laser After Application of Chromofilm®,” Journal of Cutaneous Laser Therapy, vol. 1, pp. 159-166, 1999.
Sumian, C.C. et al., “Laser Skin Resurfacing Using a Frequency Doubled Nd:YAG Laser After Topical Application of an Exogenous Chromophore,” Lasers in Surgery and Medicine, vol. 25. pp. 43-50, 1999.
Sumian et al., “A new method to improve penetration depth of dyes into the follicur duct : . . . ,” J. Am. Acad. Dermotol., 41(2) Part 1:172-175, 1999.
Tarasov, L. V., Laser Physics, Translated from Russion by Ram S. Wadhwa, MIR publishers, Moscow, pp. 178-181, Chapter 2, 1983.
Tarijian, et al., “Fractional abalative laser skin resurfacing: A review”, Journal of Cosmetic and Laser Therapy, 13:262-264, ISSN 1476/4172. Informa UK Ltd. Sep. 2011, 3 pages.
Taylor, C.R. et al., “Treatment of tattoos by Q-switched ruby laser,” Arch. Dermatol. vol. 126, pp. 893-899, Jul. 1990.
Togatov, V.V. et al., “Electronic discharge module for pump systems of solid-state lasers”, Optical Journal, V. 67, n. 4, pp. 92-96 (2000).
Tuchin, V.V., “Laser light scattering in biomedical diagnostics and therapy,” Journal of Laser Applications, vol. 5, No. 2-3, pp. 43-60, 1993.
Unger, W.P., Laser hair transplantation III: Computer-assisted laser transplanting. Dermatol Surg. 1995;21:1047-1055.
Van Bruegel, “Power Density and Exposure Time of He—Ne Irradiation Are More Important Than Total Energy Dose in Photo-Biomodulation of Human Fibroblasts in Vitro,” Lasers in Surgery and Medicine, vol. 12 pp. 528-537, 1992.
Vasily, et al., “Non-Ablative Fractional Resurfacing of Surgical and Post-Traumatic Scars”, Journal of Drugs in Dermatology, 8(11):998-1005, Nov. 2009, 8 pages.
Walsh, “Laser “Curettage”: a Critical Analysis,” Periodontology 14:4-12, 1993.
Walsh, “The Current Status of Low Level Laser Therapy in Dentistry. Part 1. Soft Tissue Applications,” Aust. Dent. J. Aug. 1997;42(4):247-54.
Watanabe, S. et al., “Comparative studies of femtosecond to microsecond laser pulses on selective pigmented cell injury in skin,” Photochemistry and Photobiology, vol. 53, No. 6, pp. 757-782, 1991.
Watanabe, S. et al., “The Effect of Pulse Duration on Selective Pigmented Cell Injury by Dye Lasers,” The Journal of Investigative Dermatology, 88:523, 1987.
Watson, G. M., MS, “Minimally Invasive Therapies of the Prostate,” Minimally Invasive Therapy, 1:231-240 (1992).
Wei Tech Ang et al., “Design of All-Accelerometer Inertial Measurement Unit for Tremor Sensing in Hand-Held Microsurgical Instrument,” 2003 IEEE International Conference on Robotics and Automation (vol. 2), Taipei, Taiwan, Sep. 14-19, 2003.
Wei Tech Ang et al., “Kalman Filtering for Real-Time Orientation Tracking of Handheld Microsurgical Instrument,” 2004 IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS), Sendai, Japan, Sep. 28-Oct. 2, 2004.
Welch, A.J. et al., “Evaluation of cooling techniques for the protection of the epidermis during HD-yag laser iradiation of the skin,” Neodymium-Yag Laser in Medicine and Surgery, Elsevier Science Publishing Co., publisher, pp. 195-204, 1983.
Westerman et al., “Argon Laser Irradiation Effects on Sound Root Surfaces: In Vitro Scanning Electron Microscopic Observations,” Journal of Clinical Laser Medicine and Surgery, vol. 16, No. 2, pp. 111-115, 1998.
Wilson, S.W., “Passive Alignment of a Semiconductor Laser to an Optical Fiber,” Universirty of Maryland, Master's Thesis (1995).
Winters, B.H. et al., “Photochemical Products in Coumarin Laser Dyes,” Appl. Phys. Lett. 25:723-724 (1974).
Yang et al., “Hybrid optoelectronics: A polymer laser pumped by a nitride light emitting diode,” Applied Physics Letters 92, Jan. 23, 2008.
Yules, R.B. et al., “The effect of Q-switched ruby laser radiation on dermal tattoo pigment in man,” Arch Surg, vol. 95, pp. 179-180, Aug. 1967.
Zapka et al. “Pulse Slicing and Pockets Cell Shutters,” J. Phys. E: Sci, Instrum., vol. 15 (1982).
Zayhowski, J.J. et al., “Gain-switched pulsed operation of microchip lasers”, Optice Letters, Optical Society of America, US 14:23, Dec. 1, 1989, pp. 1318-1320.
Zeitler, E. et al., “Laser Characteristics that Might be Useful in Biology,” Laser Applications in Medicine and Biology, vol. I, M.L. Wolbarsht, editor, Plenum Press, publishers, Chapter 1, pp. 1-18, 1971.
Zonios et al., “Skin Melanin, Hemoglobin, and Light Scattering Properties can be Quantitatively Assessed in Vivo Using Diffuse Reflectance Spectroscopy,” Journal of Investigative Dermatology,117:1452-1457 (Dec. 2001).
PCT Written Opinion for PCT International Application No. PCT/US2013/032228, dated Jun. 26, 2013, 7 pages.
Zayhowski et al., “Miniature Gain-Switched Lasers”, OSA TOPS, vol. 50, Advanced Solid-State Lasers 2001, pp. 462-469.
Duguay et al., “Picosecond Pulses from an optically pumped ribbon-whisker laser”, Applied Physical Letters, vol. 37, No. 4, Aug. 15, 1980 (pp. 369-370).
Stone et al., “Optically pumped ultrashort cavity in_1-x Ga_x As_y P_ 1-y lasers: picosecond operation between 0.83 and 1.59 μm”, Optics Letters, vol. 6, No. 11, Nov. 1, 1981, pp. 534-536.
Supplemental European Search Report for European Application No. 13778882.4, dated Dec. 1, 2015 (7 pages).
Related Publications (1)
Number Date Country
20190221989 A1 Jul 2019 US
Provisional Applications (1)
Number Date Country
61625961 Apr 2012 US
Continuations (2)
Number Date Country
Parent 15721714 Sep 2017 US
Child 16363597 US
Parent 14394960 US
Child 15721714 US